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ABSTRACT 
 
While the latent genome of most Herpesviruses persists as a nuclear circular 
episome, previous research has suggested that Human Herpesvirus 6 (HHV-6) may 
integrate into host cell chromosomes, and be vertically transmitted in the germ-line.  
Because the HHV-6 genome encodes a perfect TTAGGG telomere repeat array at the 
right end direct repeat (DRR) and an imperfect TTAGGG repeat at the end of the left end 
direct repeat (DRL), we established a hypothesis that during latency, the HHV-6A and 
HHV-6B genome integrates into the telomeres of human chromosomes through 
homologous recombination with the n(TTAGGG) viral repeats, and the integrated virus 
can be induced to lytic replication. 
We sought, first, to definitively illustrate the in vitro and in vivo integration of 
HHV-6A and HHV-6B.  Following infection of naïve Jjhan and HEK-293 cell lines by 
HHV-6A and Molt3 cell line by HHV-6B, the virus integrated into telomere of 
chromosomes.  Next, peripheral blood mononuclear cells (PBMCs) were isolated from 
families in which several members, including at least one parent and child, had 
unusually high copy numbers of HHV-6 DNA per ml of blood.  FISH confirmed that HHV-
6 DNA co-localized with telomeric regions of one allele on chromosomes 17p13.3, 
18q23, and 22q13.3, while the integration site was identical among members of the 
same family.  Partial sequencing of the viral genome identified the same integrated 
HHV-6A strain within members of families, confirming vertical transmission of the viral 
genome through the germ-line [inherited HHV-6 (iHHV-6)]. 
xii 
 
Amplification and sequencing of the HHV-6A and more recently HHV-6B viral-
chromosome junction identified DRR integrated into the telomere directly adjacent to the 
subtelomere of the chromosome.  After mapping the DRR of iHHV-6, we subsequently 
focused on determining if the DRL was present in the integrated genome and whether 
the remaining telomere sequence of the chromosome was extended beyond the DRL.  
Southern hybridization of PCR amplified HHV-6 integrated cell lines and iHHV-6 patients 
PBMCs indicate the presence of DRL within the integrated viral genome.  Moreover, the 
tandem array of telomere repeats [(TTAGGG)n] at the end of chromosome was shown to 
extend beyond the DRL of iHHV-6.  Therefore, the genomic structure of the iHHV-6 is as 
follows: chromosome-subtelomere-(TTAGGG)5-41-DRR-U-DRL-(TTAGGG)n. 
During latent integration, no circular episomes were detected even by PCR.  
However, trichostatin-A treatment of PBMCs and in vitro integrated HEK-293 cells 
induced the reactivation of iHHV-6 from its latent integrated state.  We demonstrated the 
induction of integrated iHHV-6 with trichostatin-A lead to the excision of the integrated 
genome and generation of the U-DR-U junction which signifies circularization and/or 
concatemer formation of the viral genome through rolling-circle replication.  Taken 
together, the data suggests that HHV-6A and HHV-6B are unique among human 
herpesviruses: they specifically and efficiently integrate into telomeres of chromosomes 
during latency rather than forming episomes, and the integrated viral genome is capable 
of producing virions. 
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INTRODUCTION 
 
Classification of Human Herpesviruses 
Human Herpesviruses are ubiquitous and belong to the family of Herpesviridae 
which features large enveloped virions.  The Herpesvirus virion contains a single double 
stranded DNA (dsDNA) genome ranging from 150 to 230 kbp that is packaged in an 
icosahedral capsid (1).  The viral nucleocapsid is surrounded by a proteinaceous 
tegument often consisting of proteins necessary for initiation of viral genome replication 
and degradation of cellular mRNAs.  Following the capsid and tegument layers, the 
virion is encased by an envelope that is obtained from the host cell’s plasma membrane 
or cellular organelles during the process of budding. 
Human Herpesviruses can be subdivided into three major subfamilies 
characterized by their genome sequence and structure, as well as host cell range during 
lytic and latent infection (Table 1) (1).  The Alphaherpesviruses: Herpes Simplex virus 
type 1 (HSV-1), HSV-2, and Varicella Zoster virus (VZV) infect and establish latency 
within neurons.  The Gamaherpesviruses: Epstein-Barr virus (EBV) and the Kaposi’s 
Sarcoma-associated Herpesvirus (KSHV) infect B-lymphocytes, while various malignant 
diseases can occur during latent infection.  Betaherpesviruses: Human Herpesvirus 6A 
(HHV-6A), HHV-6B, HHV-7, and Cytomegalovirus (CMV) are characterized upon their 
ability to establish latent infection in monocytes and retain similarities in their genes and 
genomic structure amongst these viruses. 
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Table 1.  Classification of Human Herpesviruses (1). 
 
Human Herpesvirus 6 (HHV-6) was initially recognized as Human B-
Lymphotropic virus (HBLV) by Salahuddin et al. in 1986, given that the virus was 
isolated from B-lymphocytes of patients infected with HIV, HTLV, and lymphoproliferative 
disorders (2). However, through further molecular and clinical studies, as well as 
sequencing of the viral genome, the virus was found to include two different species; 
HHV-6A and HHV-6B (3-6).  HHV-6A and HHV-6B have been shown to productively 
infect T-lymphocytes, monocytes/macrophages, human umbilical cord blood, and 
various cell lines (7-11). 
Furthermore, in 1988 Yamanishi et al. established that HHV-6B primary infection 
in young children is the etiological agent of exanthema subitum (roseola infantum), 
which is characterized by high fever, diarrhea, and a mild skin rash along the trunk, 
neck, and face (5, 12).  Serologic studies have found that by the age of two, 90% of 
children have acquired a primary HHV-6 infection (13, 14).  As for HHV-6A, the virus has 
been associated with several adult diseases; including cofactor in AIDS progression, and 
Designation Common Name Abbreviation Subfamily Genome Size (kbp) 
HHV-1  Herpes Simplex virus 1 HSV-1 Alpha 152 
HHV-2 Herpes Simplex virus 2  HSV-2 Alpha 155 
HHV-3 Varicella-Zoster virus  VZV Alpha 125 
HHV-4 Epstein-Barr virus EBV Gamma 172 
HHV-5 Cytomegalovirus  CMV Beta 230 
HHV-6A Human Herpesvirus 6A HHV-6A Beta 159 
HHV-6B Human Herpesvirus 6B HHV-6B Beta 162 
HHV-7 Human Herpesvirus 7 HHV-7 Beta 145 
HHV-8 Kaposi’s Sarcoma-associated Herpesvirus  KSHV Gamma 170 
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various neurological disorders including encephalitis, ataxia, seizures, and chronic 
fatigue syndrome, however the causal link between human disease and virus infection 
remains to be fully elucidated (6, 15-23). 
 
Genome Organization of Human Herpesviruses 
The genome of Human Herpesviruses are linear double-stranded DNA ranging in 
sizes from 150 to 230 kbp (1).  Human Herpesviruses also contain repetitive sequences 
longer than 100bp that vary among sequence, location, and complexity among the 
different species (Fig. 1).  Terminal repeats (TR) and direct repeats (DR) located at the 
termini of herpesvirus genomes permit circularization.  Several Human Herpesviruses 
also encode inverted repeats (IR) flanking the unique long (UL) and unique short (US) 
portion of the viral genome.  The IRs are essential for segment inversion during 
recombination, which generates multiple isomers of the viral genome.  VZV has two 
isomeric forms, while HSV-1, HSV-2, and CMV have 4 isomeric forms.  HHV-6A, HHV-
6B, HHV-7, EBV, and KSHV lack IRs that permit recombination and thus only exist as 
one isomer.   
 
Replication of Herpesviruses 
The nine known Human Herpesviruses can replicate in various cell types 
depending on their unique features.  However, the replication cycle of these 
Herpesviruses share several common features.  During the course of lytic infection, the 
viral envelope of Herpesviruses fuse with the cell’s plasma membrane and the 
nucleocapsid releases the linear viral genome into the nucleus (Fig. 2) (1).  
Subsequently the linear genome of Herpesviruses circularizes and initiates the 
expression of the so-called immediate early genes.   
4 
 
 
 
 
 
 
Fig. 1.  Genome organization of Human Herpesviruses.  The unique (U), unique long 
(UL), and unique short (US) coding region of the viral genome (solid lines) is flanked by 
terminal (TR) and inverted repeats (IR) (box regions).  The left direct repeat (DRL) and 
right direct repeat (DRR) of HHV-6A, HHV-6B, and HHV-7 encode perfect (black box) 
and imperfect (gray box) telomere TTAGGG repeats (1, 3, 4). 
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Fig. 2.  Schematic representation of lytic and latent replication of Herpesviruses.  
During lytic infection, the HHV-6A and HHV-6B viral envelope fuses with the cell’s 
plasma membrane through CD46R (24, 25).  The nucleocapsid then enters the cell and 
releases the linear viral genome into the nucleus (1).  Subsequently, the genome of 
Herpesvirus circularizes to form the viral episome and lytic or latent infection can 
proceed.  Lytic infection results in rolling-circle replication of the viral genome, cleavage 
of concatemer, viral assembly, and egress.  During latent infection, the genome 
replicates as multiple copies of episomes in the absence of virion maturation.  However, 
the integration of HHV-6A and HHV-6B into the telomere of chromosomes during latency 
will be further discussed in subsequent sections.   
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The immediate early gene products activate the viral DNA polymerase and 
replication of the viral genome occurs via rolling-circle mechanism (26, 27).  Rolling-
circle replication leads to the formation of concatemers consisting of linear viral genomes 
linked in a head-to-tail conformation that are subsequently cleaved to give rise to single 
copies of the complete viral genome.  During the last late stage of the replication cycle, 
various components of the virion are produced in large quantities, new virions are 
formed, and the infected cell dies. 
 
Maintenance of Latent Herpesviruses Genomes by Episomal Replication 
However, not all infections lead to immediate production of mature virions.  
Following primary infection, the genome of Herpesviruses can establish latency as a 
nuclear circular episome (Fig. 2) (1, 26, 27).  The expression of latent viral genes allows 
the stable replication and persistence of the latent viral genome.  During latency the 
cellular DNA polymerase and latency-associated viral genes promote genome 
replication of Herpesviruses without production of infectious virus, however the genomes 
of HSV-1 and HSV-2 do not replicate during neuronal latency.  Therefore, the central 
dogma of Herpesvirus replication is that the viral genome establishes latency as a 
nuclear circular episome and reactivation occurs through rolling-circle DNA replication 
(1, 26, 27).  However findings over the last two decades suggest this may not be the 
case as pertaining to latency of HHV-6A and HHV-6B latency (28-34).   
Luppi et al. identified the HHV-6 genome linked to a high molecular weight 
cellular DNA in peripheral blood mononuclear (PBMCs) in three patients (34).  The initial 
observation of HHV-6 integration into the human genome was confirmed by other 
laboratories (28-32); however the significance of this event, the location of viral 
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integration, and whether the integrated viral genome reactivates from its integrated state 
had not been fully characterized. 
Results completed in this dissertation demonstrate the in vivo and in vitro 
integration of HHV-6A and HHV-6B into the telomeres of human chromosomes during 
latency (33).  Moreover, HHV-6A and HHV-6B viral reactivation from its latent integrated 
state was demonstrated in patient PBMCs and in vitro integrated cell lines.  This 
dissertation details the current knowledge of HHV-6 genome structure during latent 
infections, the viral and cellular genes that could perhaps mediate integration, and lastly 
discuss the cellular as well as the clinical impact of viral integration into the telomeres. 
 
Integration of Herpesviruses and Retrotransposons into Chromosomes 
Epstein-Barr Virus 
During latency, the episomes of Herpesviruses associate with chromosomes 
through the expression of viral DNA binding proteins such as EBV nuclear antigen-1 
(EBNA-1) and KSHV’s latency-associated nuclear antigen (LANA) (35, 36).  The binding 
of EBNA1 and LANA to chromosomes is not site-specific, but this association of EBV 
and KSHV episomes with chromosomes ensures each infected cell obtains multiple 
copies of the viral episome during cell division.  However, in rare cases as shown by 
EBV, the full length genome infrequently integrates into random chromosome sites 
during latency (37, 38).  The integration of EBV into chromosomes has been 
demonstrated during long-term passage of infected cell lines and the isolation of 
reactivated virus from these cell lines has not been established. 
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Marek’s Disease Virus 
Similar to the integration of iHHV-6A and iHHV-6B into telomeres of human 
chromosomes during latency (further discussed in subsequent sections) (33), the 
Gammaherpesvirus Marek’s disease virus (MDV) frequently integrates into the telomere 
of chickens through telomeric repeats (TTAGGG)n encoded in the internal repeat short 
(IRS) of the viral genome (39-41).  MDV is acquired through inhalation of virions 
released from the dander of infected chickens.  During latency, the linear ~180 kbp 
dsDNA genome integrates into multiple telomeres of chickens in each cell.  The 
expression of viral oncogenes Meq and viral telomerase RNA (vTR) induces 
transformation of T-cells and leads to the rapid formation of solid visceral tumors and T-
cell lymphomas within two to six weeks.   
 
Retrotransposon TRAS1 
The sequence specific integration of the retrotransposable element TRAS1 
(telomeric repeat-associated sequence) was found to frequently integrate within the 
(TTAGG)n telomere repeat of the silkworm, Bombyx mori (42).  The method of 
integration occurs through cleavage of the telomere TTAGG sequence by the TRAS1 
endonculease and the fusion with the TTAGG terminal repeats encoded in TRAS1 (43).  
In summary, the specific integration of iHHV-6A and iHHV-6B into telomeres during 
latency is a novel process for a Human Herpesvirus (33).  However, the similar strategy 
of telomere integration is also employed by the avian herpesvirus MDV and the silkworm 
retrotransposon TRAS1 (39-43). 
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Genome of Human Herpesvirus 6A and 6B 
In particular, the viral genome of HHV-6B is 162 kbp long, containing 119 unique 
open reading frames (ORF), while HHV-6A genome contains 119 unique ORF and is 
159 kbp long (3, 4).  The genomic architecture of HHV-6A and HHV-6B is organized into 
two major regions (Fig. 1).  The unique (U) region of the genome which is ~143 kbp, 
contains seven major core gene blocks that are conserved amongst Herpesviruses.  
These conserved genes are responsible for replication, cleavage, and packaging of the 
viral genome into the capsid.  Additionally, these viral genes include: DNA binding 
protein, DNA polymerase, capsid, tegument, glycoproteins, and proteinase.  Also, the U 
region contains blocks of CMV related genes known as US22 family that are conserved 
amongst Betaherpesviruses.    
The second major genomic regions of HHV-6A and HHV-6B is the ~8 kbp left 
and right direct repeats (DR) located at the termini of the U region (Fig. 1) (3, 4).  Within 
the right end direct repeat (DRR) and the left end direct repeat (DRL) the HHV-6A/HHV-
6B genome encodes a perfect TTAGGG telomere repeat array and an imperfect 
TTAGGG repeat.  The viral TTAGGG repeat sequence is conserved with the telomere 
sequence of human chromosomes and also encoded within the DR of HHV-7 (44).  
Details about this telomere repeat region will be further discussed in subsequent 
sections. 
The distinction between HHV-6A and HHV-6B can not only be classified by their 
differences in clinical disease association, but also differences in their restriction 
fragment length polymorphism and the nucleotide sequence of their genomes (3, 4, 33).  
The nucleotide sequence identity between HHV-6A and HHV-6B is 90%.  The variation 
in nucleotide sequence is not only observed between HHV-6A and HHV-6B, but also 
between clinical isolates and laboratory strains of the virus.  Variability in the number of 
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telomere repeats within the DR of clinical HHV-6A and HHV-6B isolates is observed in 
the range of 15 to 180 repeats (33, 45).  Furthermore, preliminary experiments suggest 
that ORF U2 through U5 (46), as well as DR1 through the first exon of DR6 (47) are 
dispensable for in vitro viral replication.  These examples demonstrate the plasticity of 
the HHV-6 genome as well as variability in the sequences of HHV-6A and HHV-6B 
which warrant consideration for these viruses to be classified as different herpesvirus 
species rather than merely a subtype distinction between “A” and “B” (48). 
 
Pathologies and Unique Features of Human Herpesvirus 6B 
Human Herpesvirus-6 (HHV-6) was initially recognized as Human B-
Lymphotropic virus (HBLV) by Salahuddin et al. in 1986, given that the virus was 
isolated from B-lymphocytes of patients infected with HIV, HTLV, and lymphoproliferative 
disorders (2).  However, through further molecular and clinical studies, as well as 
sequencing of the viral genome, the virus was found to include two different species; 
HHV-6A and HHV-6B (3-6).  HHV-6A and HHV-6B have been shown to productively 
infect T-lymphocytes, monocytes/macrophages, human umbilical cord blood, and 
various cell lines (7-11). 
Furthermore in 1988, Yamanishi et al. established that HHV-6B primary infection 
in young children is the etiological agent of exanthema subitum (roseola infantum), 
which is characterized by high fever, diarrhea, and a mild skin rash along the trunk, 
neck, and face (5, 12).  Serologic studies have found that by the age of two, 90 % of 
children have acquired a primary HHV-6 infection due to a persistent level of HHV-6 
DNA and antibodies detected in saliva (13, 14, 49).  Few cases have also reported 
severe complications such as febrile seizures, encephalitis, hepatitis, thrombocytopenia, 
and hemophagocytic syndrome (12, 18, 50-52).  Viral reactivation has also been shown 
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to induce graft rejection in solid organ and bone marrow transplantation, seizures, and 
encephalitis (6, 16-19, 53). 
 
Pathologies and Unique Features of Human Herpesvirus 6A 
The infection of multiple cell types by HHV-6B and HHV-6A occurs through 
attachment to the complement regulator receptor CD46 (24, 25).  The diverse cell 
tropism and multiple disease associations with HHV-6A/HHV-6B are due, in part, to the 
expression of CD46 present on the surface of all nucleated cells.  In particular, HHV-6A 
has been associated with several adult diseases; including cofactor in AIDS progression, 
and various neurological disorders including encephalitis, ataxia, seizures, and chronic 
fatigue syndrome (6, 15-23).  However the causal link between human disease and virus 
infection remains to be fully elucidated. 
Results supporting HHV-6A as a co-factor in AIDS progression are based upon 
several different lines of evidence.  First, HHV-6A infection contributes to the killing of 
CD-4 lymphocytes (11, 20, 54). Second, HHV-6A and HIV co-infection of the CD4 
lymphocytes has shown to enhance HIV replication through activation of the long 
terminal repeats (LTR) (21).  However, the most compelling data was completed in a 
study by Lusso et al. in which dual infection of macaques with HHV-6A and simian 
immune virus (SIV) enhanced the progression to AIDS at a faster rate when compared 
to those macaques infected with SIV alone (20).   
Additionally, HHV-6A has a greater neurotropism when compared to HHV-6B 
due to increased concentration of viral DNA present in the plaques of patients’ brains 
with MS and its ability to establish latency in oligodendrocytes (6, 55-57).  In particular, 
Goodman et al. obtained biopsies from 5 patients brain tissue containing acute lesions 
attributed to MS (56).  In situ polymerase chain reaction detected HHV-6 DNA in 
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oligodendrocytes, microglia, and lymphocytes, while immunocytochemical staining 
identified viral antigens in microglia and astrocytes.  Cermelli et al. utilized laser 
microdissection to selectively isolate MS plaques from normal appearing white matter 
(55).  HHV-6 DNA was detected in 57.8 % of MS plaques and only in 15.9 % of normal 
appearing white matter.  However, 26.8 % of healthy brain tissue and 21.7 % of brain 
tissue from patients with various neurological disease were positive for HHV-6, which 
indicates that HHV-6 may normally reside in the brain (58). 
Several investigators reported an increase in anti-HHV-6 IgG and IgM antibody 
titers and HHV-6A DNA and RNA during clinical relapse of MS compared to controls (59-
61).   HHV-6 DNA was also detected in the CSF and brain tissues at higher levels than 
control individuals (55, 62).  Interestingly, markers of HHV-6 infection increased during 
relapse and decreased during remission (60, 63).  In summary, these reports suggest 
HHV-6A may have a role in MS progression; however the interpretation of these findings 
remains uncertain. 
 
Chromosome Integration of the Human Herpesvirus 6 Genome 
Primary infection of HHV-6 leads to an increase in viral copies present in 
peripheral blood of children and subsequent decrease in viral copies during latency (5, 
12-14, 16).  The genome of Herpesviruses forms a nuclear circular episome during 
latency and the minimal amounts of viral genes are expressed to allow the stable 
replication of the viral genome.  However, in a select number of patients including adults 
and children, there are high copies of HHV-6 genome consistently detected in peripheral 
blood measuring greater than 1 million copies per ml or 1 copy of HHV-6 per cell (31, 33, 
64, 65).  Moreover, Jarrett et al. identified a patient with HHV-6 detected in multiple 
tissues which is suggestive of germ-line transmission (66).  In 1993 Luppi et al. identified 
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a unique high molecular weight viral fragment present in PBMCs of three patients with 
elevated copies of HHV-6 (34).  This high molecular weight fragment resolved by pulse 
field gel electrophoresis demonstrated one of the earliest observations of viral integration 
into the genome.  Subsequently, several other labs have shown integration of HHV-6 
into human chromosomes through fluorescent in situ hybridization (FISH) and PCR 
amplification allowed for the detection of HHV-6 sequences in hair follicles, lymph node, 
spleen, kidney, brain, liver and cardiac tissues (28, 29, 31, 66, 67).  The FISH assay 
however, cannot distinguish non-covalent linkage of viral episomes from integration or 
establish the specific site of viral integration.  
Despite previous publications (28-32, 34, 64-66), investigators lacked conclusive 
results supporting the integration of HHV-6 into chromosomes and whether the 
integrated viral genome represented a latent infection remained unanswered.  Therefore, 
these questions will be addressed in subsequent sections. 
 
Telomere Biology 
The human telomere is a repetitive TTAGGG dsDNA sequence extended from 
the end of chromosomes (Fig. 3) (68-70).  The telomere repeat is bound by a set of 
proteins that form the shelterin complex. TTAGGG repeat factor 1 (TRF1), TRF2, and 
protection of telomeres 1 (Pot1) directly bind to the telomeric TTAGGG repeat.  The 
shelterin complex is then maintained through interaction with TRF1-Interacting Nuclear 
Factor 2 (TIN2), TPP1 (TINT1, PIP1, PYOP1), and Repressor Activator Protein 1 
(RAP1).  Until recently, telomeres were believed to be transcriptionally silent; however 
mammalian telomeres were shown to transcribe telomere-repeat-encoding RNA 
(TERRA) (71).  TERRA stabilizes the shelterin complex and facilitates telomere 
heterochromatin formation through direct interaction with TRF1 and TRF2 (72).  
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Therefore, the repetitive TTAGGG telomere sequence, shelterin complex, and TERRA 
protect the ends of chromosomes from double stranded breaks, chromosome fusions, 
and inhibit telomerase mediated lengthening (68-72). 
The telomere length in somatic cells is 5-15 kbp and after every cell division, 
250-300 bp are lost from the end of telomeres due to the challenges encountered with 
the process of end replication (70).  The Hayflick limit occurs when telomeres reach a 
critical length, and cells undergo replicative senescence or apoptosis (73).  Telomeres 
can be lengthened by telomerase reverse transcriptase (TERT) through the addition of 
the TTAGGG repeat (70).  Telomerase mediated telomere lengthening has been 
detected in germ-line cells, cancer cells, and stem cells (74).  
 
 
 
Fig. 3.  Diagram of the shelterin complex and TERRA maintenance of telomere 
ends.  The double stranded repetitive TTAGGG telomere sequence (black lines) is 
bound by the TRF1 and TRF2, while the interaction of POT1 with the 3’ end of the 
telomere promotes strand invasion of the telomere duplex-loop (not shown) (68-70).  
TERRA (red line) stabilizes the shelterin complex and facilitates telomere 
heterochromatin formation through the direct interaction with TRF1 and TRF2 (72).  
Collectively, the shelterin complex inhibits telomerase mediated lengthening, double 
stranded breaks, and chromosome fusions (68-72). 
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Shay et al. estimated that 85 % of all malignant and transformed cells utilize 
telomerase to lengthen their telomeres to prevent telomere attrition (74).  However, 
telomere length can also be maintained through the recombination mediated alternative 
lengthening of telomeres (ALT) (75, 76).  The mechanism of ALT has yet to be fully 
characterized; however one method suggests that circular extrachromosomal telomeric 
repeats (T-circle) formed from the lost of the telomere-loop (T-loop) at the end of 
telomeres may serve as a template for telomere lengthening through rolling-circle 
replication (77-80).  Similar to the replication of T-loops, the circular episome of 
herpesviruses also replicate through rolling-circle replication which leads to the formation 
of viral concatemers (Fig. 2) (26, 27). 
The integration of HHV-6A and HHV-6B into telomeres is a newly identified form 
of human herpesvirus latency that will be discussed in this dissertation (33).  The 
knowledge attained from the virus telomere biology may play a critical role in 
understanding the process of virus replication and integration.   
 
Significance 
HHV-6A and HHV-6B have been identified as  cofactors in AIDS progression, 
graft rejection in transplants, as well as associated with MS and various neurological 
symptoms (6, 16-21, 53, 55-57).  Furthermore, 90 % of the population has acquired a 
primary HHV-6 infection by three years of age (13, 14).  The prevalence of high HHV-6 
viral load (106-107 copies per ml of blood) has been described in several British cohorts 
(64, 65) attributed to chromosome integration of HHV-6.  The prevalence of high viral 
loads in normal blood donors was 0.8 % (4/500) (64) and 1.0 % (57/5638) (81) .  In 
contrast, prevalence of integrated HHV-6 in hospitalized patient cohorts was higher, 2.9 
% (13/449) (64) and 3.3 % (6/184) (65).  Therefore, it’s essential that investigators 
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determine the overall clinical impact the integrated virus may have on hospitalized 
patients and disease progression.  As a result, the significance of this dissertation is the 
characterization of the novel mechanism by which HHV-6A and HHV-6B integrates into 
telomeres of human chromosomes during latency and the reactivation of the integrated 
virus to lytic replication. 
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OBJECTIVES 
 
HYPOTHESIS:  During Latency, the Human Herpesviruses 6A and 6B Genome 
Integrates into the Telomeres of Human Chromosomes through Homologous 
Recombination with the n(TTAGGG) Viral Repeats, and the Integrated Virus can 
be Induced to Lytic Replication 
 
AIM I.  To Determine whether the Human Herpesviruses 6A and 6B Genome Integrates 
into Chromosomes of in vitro Infected Cell Lines 
 
AIM II.  To Determine that Human Herpesviruses 6A and 6B Genome Integrates into the 
Telomeres of Patients through Germ-Line Transmission 
 
AIM III.  To Determine if the Telomere Integrated Human Herpesviruses 6A and 6B 
Genome can Reactivate from Latency and Produce Infectious Virus 
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MATERIALS AND METHODS 
 
Cell Lines, Primary Human T-cells, Media, and Virus Strains 
Heparinized peripheral blood from four families with germ-line inherited HHV-6 
(iHHV-6) was obtained by the HHV-6 Foundation (Table 11), after the subjects had 
given informed consent.  PBMCs were isolated by diluting peripheral blood with an equal 
volume of RPMI-1640 and slowly pipetted onto isotonic density gradient of 
Lymphoprep™ (Axis-Shield, Oslo, Norway).  Since Lymphoprep™ has a density of 
1.077 g/ml, mononuclear cells can be isolated from the interphase while erythrocytes 
and granulocytes form a pellet (82).  Samples were centrifuged for 30 min at 800 x g, 
25°C.  Mononuclear cells were isolated from the buffy coat located at interphase, 
resuspended in RPMI-1640, and centrifuged for 10 min at 250 x g, 25°C.  The pellet of 
mononuclear cells was then resuspended  in RPMI-1640 media containing 10 % FBS 
and 5 μg/ml PHA (Sigma-Aldrich, St. Louis, MS) for 72 hrs followed by culturing in 100 
U/μl IL-2 medium to promote the expansion of primary T-cells.   
T-cell lines Jjhan (HHV-6 Foundation), Molt3 (ATCC), and Burkitt’s lymphoma 
cell line Raji (ATCC) were maintained in RPMI-1640 complete medium containing 10% 
FBS and 50 µg/ml gentamicin sulfate.  Human embryonic kidney-293 cells (HEK-293) 
were maintained in DMEM supplemented with 10 % FBS and 50 µg/ml gentamicin 
sulfate.  HHV-6A (U1102 strain) and HHV-6B (Z29 strain) viruses were supplied by P. 
Pellett (Wayne State University).  HHV-6 integrated Burkitt’s lymphoma cell line Katata 
was supplied by M. Daibata (Kochi Medical School, Japan) (83).   
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Human Herpesvirus-6 in vitro Integration and Infection of Cell Lines 
To evaluate if HHV-6 frequently integrates in culture, we infected both T-cell lines 
and HEK-293 cells (Table 2).  To begin, HEK-293 cells cultured at 50 % confluency 
were infected with HHV-6A (U1102) at 0.1 multiplicity of infection (MOI).  The cultures 
were incubated for five days.  Then the cells were washed to remove extracellular virus, 
and single cells were introduced in each well of a 96 well plate.  Single HEK-293 cell 
clones were expanded and genomic DNA was isolated through Wizard® Genomic DNA 
Purification Kit (Promega, Madison, WI), while remaining cells were stored at -80 ºC in 
10 % DMSO and FCS.  To determine which clones were successfully infected with HHV-
6A, the presences of the viral genome was determined by PCR for ORF U94 (Table 6) 
and agarose gel electrophoresis.  Evaluation of in vitro HHV-6A integration was 
competed by FISH with HHV-6 cosimd probes (Table 3) (84) and inverse-PCR coupled 
with Southern blot hybridization (85). 
Moreover, HHV-6A and HHV-6B infection and integration was evaluated in two 
T-cell lines (Table 2).  In these experiments, the T-cell line Jjhan was infected with HHV-
6A (U1102) and the T-cell line Molt3 was infected with HHV-6B (Z29).  After removal of 
dead cells through Lymphoprep™ isotonic density gradient, 107 T-cells were infected 
with HHV-6A and HHV-6B at 1.0 MOI in 1 ml of RPMI-1640 complete for 2 hrs at 37°C.  
Unabsorbed virus was removed by centrifugation for 5 min at 1,500 rpm, 25°C.  Cell 
pellet was resuspended to 106 cells/ml and incubated at 37 ºC, 5 % CO2.  DNA was 
prepared from cells at the peak of cytopathic effect (CPE) (5 – 14 days), containing ~103 
infectious units/ml of virus.  HHV-6A and HHV-6B viral integration into T-cell lines (Jjhan 
and Molt3) were evaluated by amplification of the viral genome-telomere junction using 
chromosome specific primers (Table 8).  Southern blot hybridization and sequencing of 
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pCR®4-TOPO® (TOPO TA Cloning® Kit for Sequencing, Invitrogen, Carlsbad, CA) clones 
confirmed chromosome integration.    
 
Table 2.  HHV-6A and HHV-6B chromosome integrated cell lines. 
Cell lines Virus Description 
HEK-293  HHV-6A Three single cell clones derived 
Jjahn (T-cell) HHV-6A Mixed infection 
Molt3 (T-cell) HHV-6B Mixed Infection 
Katata [ref. (83)] HHV-6B EBVNegative Burkitt’s lymphoma 
 
Immortalization of Human Herpesvirus 6 Integrated T-cells using Herpesvirus 
saimiri 
Immortalization of iHHV-6 positive patient T-cells (Table 12) with Herpesvirus 
saimiri (HVS) strain 484-77 was used to generate lymphoidblastoid cell lines (LCL) (86, 
87).  A semi-confluent monolayer of owl monkey kidney (OMK) cells in a 100 mm-dish 
was infected with about 106 pfu/ml (plaque forming units) of HVS strain 484-77.  Once 
OMK cells presented CPE (2 – 3 days), media was collected, and HVS virus present in 
the supernatant was concentrated by high-speed centrifugation in a SW28 rotor for 1 hr 
at 20,000 rpm.  Human PBMCs were then harvested through Lymphoprep™ isotonic 
density gradient followed by T-cell expansion through PHA and IL-2 stimulation.  Patient 
T-cells (2 x 107) were then infected with HVS and cultured in AIM V medium (Gibco) 
supplemented with 20 U/ml IL-2.  Lymphoidblastoid cell lines were achieved roughly 
after 3 months in culture and these cell lines continuously divided in the absence of IL-2.  
 
Reactivation of Chromosome Integrated Human Herpesvirus 6 
Human PBMCs were either harvested through Lymphoprep™ isotonic density  
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gradient or through incubating with RBC Lysis Solution (Bioworld Consulting 
Laboratories, LLC) according to manufactures’ instructions.  Reactivation of iHHV-6 was 
then achieved through culturing 1x106 PBMCs per ml in RPMI-1640 medium 
supplemented with 10 % FCS, 20 ng/ml TPA, and 1x10-6 M hydrocortisone or 80 ng/ml 
TSA for 3 to 5 days.  To isolate reactivated virus, 1x104 Molt-3 cells were added to 106 
PBMCs and cultured for 10 – 14 days.  Reactivation was monitored for cell CPE (cell 
lysis and syncitia), Gardella gel, qPCR, and sequencing of ORF U94. 
 
Isolation of Human Herpesvirus 6 Genomic DNA from Mammalian Cells 
Isolation of cellular and iHHV-6 genomic DNA from mammalian cells began by 
centrifuging 5 min at 500 x g, 4°C to pellet cell suspension.  Supernatant was discarded 
and cells were resuspended with 10 ml ice-cold PBS and centrifuged centrifuging 5 min 
at 500 x g, 4°C.  PBS resuspension and centrifugation was repeated for a second time to 
remove any remaining contaminating material.  Cell pellet was resuspended with 100 µl 
PBS followed by the addition of 1.0 ml of lysis buffer and incubated for 12 – 18 hrs at 
50°C.  Lysis buffer contained 100 mM NaCl, 10 mM Tris-HCl (pH 8.0), 25 mM EDTA (pH 
8.0), 0.5 % SDS, and 0.1 mg/ml proteinase K.  Genomic DNA was then extracted twice 
with an equal volume of phenol and centrifuged 10 min at 1700 x g, room temperature 
(RT).  The aqueous phase was removed from the top layer and extracted with an equal 
volume of chloroform/isoamyl alcohol (24:1) and centrifuged for 10 min at 1700 x g, RT.  
The top aqueous phase was removed and DNA was precipitated by mixing 0.3 M 
ammonium acetate, 2.5 volumes of ice-cold 96 % ethanol, and incubating 20 min at -
80°C.  Precipitated DNA was then centrifuged for 20 min at 4000 x g, 4°C.  Next, pellet 
was rinsed with 70 % ethanol, centrifuged for 5 min at 4000 x g, 4°C, and air dried for 10 
– 20 min.  DNA pellet was then dissolved in TE buffer and stored at 4°C. 
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Alternatively, genomic DNA was isolated from whole blood and PBMCs with the 
Wizard® Genomic DNA Purification Kit (Promega, Madison, WI) according to the 
manufacture instructions.  DNA concentration and purity was determined by agarose gel 
electrophoresis compared to known concentration of λHindIII ladder or through 
spectrophotometer analysis of A260:A280 absorbance ratio (NanoDrop 
Spectrophotometer, ND-1000, Thermo Scientific, Wilmington, DE).  DNA samples with 
an A260:A280 ranges of 1.8 – 2.0 were utilized for downstream experiments. 
 
Identifying Chromosome Integrated Human Herpesvirus 6 
Gardella Gel Analysis 
The vertical agarose gel technique of Gardella et al. is capable of distinguishing 
cellular genomic DNA, covalently closed circular DNA (viral episomes), and replicating 
linear viral DNA (Fig. 4) (88).  This occurs through the gentle release of DNA by in situ 
lysis within the loading well of the vertical agarose gel followed by the application of an 
electric current.  To begin, living lymphoid cells were first isolated from dead cells 
through the isotonic density gradient of Lymphoprep™ (Axis-Shield, Oslo, Norway) as 
previously described.  Following, 1×106 cells were resuspended in 80 µl of sample buffer 
(15 % Ficoll, 0.01 % bromophenol blue in TBE buffer) and could either be stored at -
80°C or directly loaded into the wells of a 0.8 % vertical agarose gel.  Cells were then 
lysed in situ by layering with cell lysis solution (5 % Ficoll, 1 % SDS, 1 mg/ml pronase) 
and electrophoresed 0.8 V/cm (22 V) for 3 hrs followed by 7.5 V/cm (70 V) for 14 hrs at 
4°C in TBE buffer. 
The DNA in the gel was visualized through ethidium bromide staining coupled 
with the Gel Doc™ XR+ system equipped with a CCD camera (Universal Hood II, Bio-
Rad, Hercules, CA).  Alternatively, to increase sensitivity, the gel was stained with 20 µl 
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of SYBERGreen™ Nucleic Acid Stain (Lonza Rockland Inc., Rockland, ME) diluted in 
200 ml of 1 X TBE buffer for one hour.  The gel was then de-stained with 200 ml of 1 X 
TBE for 30 min and the DNA is then visualized using the Molecular Dynamics STORM 
Phosphor Imager (Model 860-PC, Amersham Biosciences, Piscataway, NJ).  Next the 
DNA was transferred to nitrocellulose and Southern hybridized with [α32P]-dATP labeled 
HHV-6 cosmids and [γ32P]-ATP labeled mintochondrion oligonucleotides probes (Tables 
3 and 4) (84, 85, 89).   
 
 
 
Fig. 4.  Diagram of vertical agarose gel of Gardella et al. (88).  A suspension of 1 x 
106 cells in sample buffer is loaded into the wells of a vertical agarose gel.  Cells were 
then lysed in situ by layering with cell lysis solution followed by the application of an 
electric current.  The high molecular weight cellular DNA is located in the loading well of 
the gel, while covalently closed circular episomal DNA is in the middle of the gel and 
linear viral DNA migrates at a faster rate toward the bottom of the gel. 
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Table 3.  HHV-6A cosmids utilized for synthesis of [α32P]-dATP probes (84). 
HHV-6A (U1102) Cosmid Sequence Location 
PMF311-12 65 – 75 kbp 
PMF335-6 50 – 72 kbp 
 
Table 4.  Oligonucleotides for [γ32P]-ATP labeled mitochondrion probes (89). 
Oligonucleotide Name Sequence 
2R  5’-TGGACAACCAGCTATCACCA-3’ 
7F 5’-ACTAATTAATCCCCTGGCCC-3’ 
7R 5’-CCTGGGGTGGGTTTTGTATG-3’ 
13F 5’-TTTCCCCCTCTATTGATCCC-3’ 
13R 5’-GTGGCCTTGGTATGTGCTTT-3’ 
17F 5’-TCACTCTCACTGCCCAAGAA-3’ 
17R 5’-GGAGAATGGGGGATAGGTGT-3’ 
22F 5’-TGAAACTTCGGCTCACTCCT-3’ 
22R 5’-AGCTTTGGGTGCTAATGGTG-3’ 
 
Fluorescent in situ Hybridization 
Patient PBMCs were stimulated for 72 hrs with PHA followed by the preparation 
of metaphase chromosomes according to standard cytogenic protocol (90).  Viral 
integration was observed by HHV-6A (U1102 strain) pMF311-12 and PMF335-6 cosmid 
(84) probes labeled with Fluorescein (Table 3).  Subsequently, HHV-6 chromosomal 
integration sites were hybridized with probes for the centromere of chromosome 17 
(Vysis), BCL2 gene on chromosome 18 (Vysis), EWSR1 gene on chromosome 22 
(Vysis), and telomere-PNA probe (DakoCytomation).  DAPI was then used to visualize 
metaphase chromosomes with Axiophot microscope (Zeiss, Austria).  At least 11 
metaphase spreads were examined per a sample.   
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FISH experiments were performed in two independent laboratories (University of 
Minnesota, Minneapolis, MN and the Children’s Cancer Research Institute, Vienna, 
Austria).  Each laboratory was blind to knowledge of the individual and family 
membership from which each specimen had been obtained (Table 12). 
 
CsCl/Ethidium Bromide Density Gradient 
The CsCl/Ethidium bromide density gradient enables the segregation of 
covalently closed circular DNA (cccDNA) from linear DNA.  Cesium chloride (CsCl) (1.55 
g/ml) and ethidium bromide (EtBr) (1 µg/ml final concentration) was added to DNA (50 
µg) isolated from HEK-293 (Table 2) and family member T-cells with integrated iHHV-6 
(Table 12).  The volume and density of the gradient was adjusted with the addition of TE 
and Cs/Cl to a final density of 1.55 g/ml as determined with the use of analytical balance 
(Mettler, AE50).  The samples were then centrifuged in a Beckman L7-75 (VTi65 rotor) 
for 72 hrs at 45,000 rpm, 20°C.  Following centrifugation, 200 µl fractions from the 
gradient were collected in a 96-well plate.  Aliquots from each fraction were then 
analyzed by electrophoresis in a 0.8 % agarose gel running at 1.2 V/cm in TBE buffer.  
The high density fractions of cccDNA and the lower density fraction of linear DNA were 
combined in separate aliquots.   
The linear DNA and cccDNA fractions were purified of ethidium bromide by 
repeated extractions with 1 volume of isopropanol saturated with 5 M NaCl and 
centrifugation for 3 min at 1500 x g, RT.  The DNA from the lower aqueous phase was 
then precipitated by mixing 1 volume of H2O and 2.5 volumes of 95 % ethanol, incubated 
for 30 min at -80°C, and centrifuged for 30 min at 20,000 x g, 4°C.  Remaining salts were 
removed by washing with 70 % ethanol and the DNA pellet was then air dried to remove 
trace amounts of ethanol followed by resuspension in 1 X TE buffer. 
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To confirm the independent isolation of cccDNA and linear DNA, PCR with 
REDTaq® DNA Polymerase (Sigma, St. Louis, MS) was utilized in combination with four 
primer sets (Table 5).  Isolation of linear DNA was confirmed with primers to cellular 
encoded beta actin (91) and cccDNA fraction was confirmed by amplification of the 
mitochondrion encoded cytochrome-C oxidase (92).  The distinction between the 
integrated genome of iHHV-6 from episome cccDNA fractions was determined through 
amplification of ORF U94, while the HVS (strain C484) genome was detected using 
primers to Stp oncogene.  
 
Table 5.  Oligonucleotides for CsCl/Ethidium bromide density gradient. 
Oligonucleotide Name Sequence 
HVS C484 Stp-F  5’-CTCAGAACGCGGCAACAAACTTGA-3’ 
HVS C484 Stp-R  5’-TTTCGGCATACCTGGATCCCATGA-3’ 
Cytochrome-C oxidase-F [ref. (92)] 5’-TTCGCCGACCGTTGACTATT-3’ 
Cytochrome-C oxidase-R [ref. (92)] 5’-AAGATTATTACAAATGCATGGGC-3’ 
Beta actin-F [ref. (91)]  5’-CTGGAACGGTGAAGGTGACA-3’ 
Beta actin-R [ref. (91)] 5’-AAGGGACTTCCTGTAACAATGCA-3’ 
HHV-6 ORF U94-F 5’-ACAGCCATTCGATGGTTCCCAGAA-3’ 
HHV-6 ORF U94-R 5’-AACGAACTGGGAGACGTATGCGAT-3’ 
 
Agarose Gel Electrophoresis and Southern Blot Analysis  
Agarose gel electrophoresis of DNA was carried out in 1 X TBE buffer (20 X 
stock: 890 mM tris base, 890 mM boric acid, pH 8.0 HCl), staining with ethidium 
bromide, and visualized with Gel Doc™ XR+ system equipped with a CCD camera 
(Universal Hood II, Bio-Rad, Hercules, CA) .  In preparation of Southern blotting (85), the 
agarose gel was incubated and gently rocked twice for 15 min in the following solutions: 
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1) 0.25 M HCl solution for DNA depurination; 2) 1 M NaCl, 0.5 M NaOH solution for DNA 
denaturation; and 3) 1.5 M NaCl, 0.5 M Tris-HCl (pH 7.0) solution to neutralize.   
The DNA from buffered agarose gels were transferred to supported nitrocellulose 
or positively charged nylon membranes (Amersham Biosciences) through vacuum-
blotting (93).  A solution of 1 X SSC (Saline-sodium citrate) diluted from a 20 X stock 
buffer (3 M NaCL, 0.3 M sodium citrate, pH 7.0) was continuously applied to the top of 
the agarose gel during the 30 – 45 min transfer.  DNA was then immobilized to the 
membrane by baking for 1 h in a vacuum oven at 80°C.  Membranes were blocked for 
nonspecific binding of the radiolabeled probes by incubating 10 ml of pre-hybridization 
buffer [50 % formamide, 5 X SSC, 10 X Denhardt’s solution (0.2 % bovine serum 
albumin, 0.2 % Ficoll 400, and 0.2 % polyvinylpyrrollidone), 0.5 mg/ml sonicated salmon 
sperm DNA (or total E.coli DNA), 0.05 M Na3P04 (pH 6.5), and 0.1 % SDS] that had 
been previously boiled for 5 min.  During the 10 – 30 min incubation of membranes at 
42°C with pre-hybridization buffer, [α32P]-dATP labeled vector DNA is added to 10 ml of 
hybridization buffer [50% formamide, 5 X SSC, 1 X Denhardt’s solution, 0.1 mg/ml 
sonicated salmon sperm DNA (or total E. coli DNA), 0.015 M Na3P04 (pH 6.5), and 0.1 % 
SDS] and boiled for 5 min to denature the probe.  Alternatively, [γ32P]-ATP labeled 
oligonucleotide probes are added to room temperature hybridization buffer.  Once pre-
hybridization buffer is removed from the membrane, hybridization buffer with 
radiolabeled probe is incubated for 16 – 18 hrs while rocking either at room temperature 
for [γ32P]-ATP labeled oligonucleotides or 42°C for [α32P]-dATP random primer labeling. 
The membrane is then washed with 3 – 4 times in a solution containing 0.1 X 
SSC and 0.1 % SDS.  The wash solution is either room temperature for [γ32P]-ATP or 55 
– 60°C for [α32P]-dATP.  Membranes were sealed in plastic wrap and exposed to a 
Storage Phosphor Screen (Molecular Dynamics, Sunnyvale, CA) for 8 hrs – 14 days and 
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analyzed using a Molecular Dynamics STORM Phosphor Imager (Model 860-PC, 
Amersham Biosciences, Piscataway, NJ). 
 
Synthesis of 32P-Radiolabeled DNA Probes 
Oligonucleotide probes were first diluted to a final concentration of 10 ng/µl.  
Next, oligonucleotides were then end-labeled with [γ32P]-ATP by adding 1.0 µl of 10 X T4 
polynucleotide kinase buffer, 1.0 µl (10 U) of T4 kinase (Promega, Madison, WI), 7.0 µl 
of [γ32P]-ATP isotope (PerkinElmer, Boston, MA), and 1.0 µl (10 ng/µl) oligonucleotide 
that serves as the probe.  The kinase reaction then proceeded for 30 min at 37°C.  Then, 
50 µl stop buffer consisting of 50 mM EDTA, 20 mM Tris-HCl (pH 7.5), 20 mM NaCl, 
0.25 % dextran blue, and 1 % SDS was added.  The radiolabeled oligonucleotide probes 
were incubated at room temperature for 16 -18 hours with the DNA vacuum-blotted 
membrane or stored at 4°C until use. 
Synthesis of random primer [α32P]-dATP-radiolabeling of plasmid probes begins 
by mixing 3 µl (20 - 100 ng) of plasmid and 3 µl of random primers (500 ng/µl) and 
denatured for 3 min at 100°C.  The microfuge tube is then immediately placed on ice for 
5 – 10 min to allow annealing of random primers to the plasmid sequence.  Incorporation 
of [α32P]-ATP into plasmid sequence is achieved by adding 1.5 µl of 10 X DNA 
polymerase buffer, 1.0 µl DNA polymerase I large fragment-Klenow (5 U) (Promega, 
Madison, WI), 1.5 µl of 500 µM dNTP-ATP, 5.0 µl [α32P]-dATP isotope (PerkinElmer, 
Boston, MA), and incubated at room temperature for 4 hrs.  Then, 45 µl stop buffer is 
added to the probe and unincorporated [α32P]-ATP is then removed by applying the 
probe to a DNA cellulose column.  The radiolabeled probe is either incubated at 42°C for 
16 -18 hours with the DNA vacuum-blotted membrane or stored at 4°C. 
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Quantitative Real-Time PCR (qPCR) 
Patient T-cells positive for iHHV-6 and HHV-6A in vitro integrated HEK-293 cells 
were treated for three days with TPA (20 ng/ml) and TSA (80 ng/ml) to see if reactivation 
of the chromosome integrated virus leads to an increase in viral copies.  To investigate 
this, DNA was isolated from treated and untreated (control) cells and subjected to 
quantitative real time PCR (qPCR) for HHV-6 encoded ORF U94 and normalized to the 
house keeping gene beta actin.  DNA samples were analyzed in triplicate and 10 fold 
serial dilutions of U94-pZeoSV plasmid was used to generate a standard curve.  For 
negative controls, a no template control and genomic DNA from a HHV-6 negative cell 
line was analyzed with every set.  The master mix for each reaction contained: 100 ng 
template DNA, 12.5 µl of Syber® Green JumpStart™ Taq ReadyMix™ for Quanitative 
PCR (Sigma-Aldrich, St. Loius, MO), 0.25 µ internal reference dye, 1 µl of 5 µm stock of 
forward and reverse primers for ORF U94 and beta actin (Table 6), and the volume was 
increased to 25 µl with H2O.   
 
Table 6.  Oligonucleotides for quantitative real-time PCR. 
 
The samples were then analyzed with Chromo4 Real-Time PCR Detector (BIO 
RAD, DNAEngine) using the following thermocycling parameters: 94°C for 2 min, which 
is the followed by 40 cycles of  94°C for 15 sec, 60°C for 1 min, and 72°C for 30 sec.  
Next, a melt-curve ranging from 45°C to 90°C with 0.2 ºC increase every 2 sec was 
Oligonucleotide Name Sequence 
Beta actin-F [ref. (91)] 5’-CTGGAACGGTGAAGGTGACA-3’ 
Beta actin-R [ref. (91)] 5’-AAGGGACTTCCTGTAACAATGCA-3’ 
HHV-6 ORF U94-F 5’-ACAGCCATTCGATGGTTCCCAGAA-3’ 
HHV-6 ORF U94-R 5’-AACGAACTGGGAGACGTATGCGAT-3’ 
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completed to ensure that fluorescence signal recorded by Syber® Green was the result 
of the specific amplification of beta actin and ORF U94.  Data was then analyzed with 
DNA Engine Software.  Fold change ratios of Ct values normalized to beta actin were 
relative to untreated control.  Statistical analysis was completed with the student T-test 
and p < 0.05 was considered significant.   
 
Cloning the Chromosome Integration Site of Human Herpesvirus 6 
Inverse PCR 
Inverse PCR (IPCR) amplification of the HHV-6 integration site was adapted from 
Ochman et al. (94) (Fig. 5).  Briefly, 2 μg of patient genomic DNA was restriction 
digested with 10 U of MboI (Promega) for 14 hrs at 37°C.  To allow monomeric 
circularization and prevent ligation of several fragments, MboI-digested DNA was diluted 
to 2 μg/ml, and ligated with 0.045 U/μl T4 DNA ligase (Promega) for 14 hrs at 15°C.  
Amplification of 100 ng of ligated DNA was performed with primers IPCR-1 and IPCR-2 
(Table 7) along with Expand 20 kbPLUS PCR System (Roche Diagnostics, Mannheim, 
Germany).  Identification of HHV-6 integration site was then achieved by agarose gel 
electrophoresis and Southern hybridization with IPCR-probe to HHV-6 and telomere 
repeat [γ32P]-ATP-radiolabeled oligonucleotides. 
 
Table 7.  Oligonucleotides for IPCR amplification and probe. 
 
Oligonucleotide Name Sequence 
IPCR-1 5-’GCACAACCCACCCATGTGGTAGTCGCGG-3’ 
IPCR-2 5’-CGTGTGTACGCGTCCGTGGTAGAAACGCG-3’ 
IPCR-probe 5’-CTTACACTTGCCATGCTAGC-3’ 
Telomere repeat-probe 5’-TTAGGGTTAGGGTTAGGGTTAGGG-3’ 
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Fig. 5.  Diagram illustrating the amplification of HHV-6-chromosome junction by 
inverse-PCR (IPCR).  Hypothesis: integration of HHV-6 occurs within the telomere of a 
human chromosome via homologous recombination with the TTAGGG perfect repeats 
within direct repeat right (DRR) (Fig. 1).  IPCR involves digestion of genomic DNA with 
MboI followed by self-circularization of HHV-6 DRR and adjacent chromosomal fragment. 
PCR amplification of HHV-6-chromosome fragment is achieved through HHV-6 primers 
IPCR-1 and IPCR-2.  Co-hybridization with IPCR-probe and telomere probe via 
Southern hybridization identified the HHV6-telomere-chromosome junction.  DRL, direct 
repeat left; U, unique. 
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Chromosome-Specific PCR for iHHV-6 Integration 
Both copies of the HHV-6 DR are bounded on their left by an imperfect TTAGGG 
repeats and on their right by perfect arrays of the TTAGGG sequence.  Thus, the right 
end of the viral genome has a perfect TTAGGG array that derives from DRR and the left 
end of the genome has an imperfect array that derives from DRL  (3, 4).  To amplify and 
sequence the putative viral-chromosomal DNA junction, we created a primer pair 
homologous to the DRL and DRR of the viral genome, as well as a primer to the 
subtelomere of a specific chromosome (Fig. 6).  The chromosome subtelomere primer 
was selected based upon results from FISH of iHHV-6 (Fig.15). 
 
 
Fig. 6.  Strategy of chromosome-specific PCR for iHHV-6 integration.  The putative 
HHV-6-chromosome junction was amplified with a primer to the specific end of 
chromosome subtelomere and the second primer derived from the (a) HHV-6 right direct 
repeat (DRR) or (b) the left direct repeat (DRL).  Both primers to DRR and DRL were 
utilized since we were unaware whether iHHV-6 integration occurs via the left or right 
telomere encoded repeats.  Arrows indicate position of primers. Unique = U. 
 
The PCR master mix for amplification of iHHV-6 integration site included: 400 ng 
genomic DNA, HHV-6 DRR/DRL and chromosome specific primers (50 µM) (Table 8), 
500 µM dNTPs, Expand 20 kbPLUS PCR system (Roche Diagnostics, Indianapolis, IN), 10 
X taq buffer, and final volume was increased to 25 µl with H2O.  Samples were placed in 
a Peltier Thermal Cycler PCR (PTC-220, MJ Research Inc, Waltham, Ma) and subjected  
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to the following PCR conditions: 94°C for 2 min, which is the followed by 35 cycles of 
94°C for 10 sec, 64°C for 30 sec, and 68°C for 10 min, and finished with a final 
extension of 68°C for 7 min.   
Agarose gel electrophoresis and Southern blot hybridization with telomere, HHV-
6, and chromosome specific [γ32P]-ATP-radiolabeled oligonucleotide probes was utilized 
for identifying DNA bands representing the putative viral-chromosomal DNA junction.  
Specific bands were gel extracted with Perfectprep® Gel Cleanup Kit (Eppendorf, 
Westbury, NY) and cloned with pCR®4-TOPO® (TOPO TA Cloning® Kit for Sequencing, 
Invitrogen, Carlsbad, CA).  A minimum of three clones from each sample was 
sequenced by the Molecular Biology core facility at H. Lee Moffitt Cancer Center and 
Research Institute. 
 
Table 8.  Oligonucleotides for chromosome-specific PCR and probe. 
Oligonucleotide Name Sequence 
HHV-6 DRR 5’-CATAGATCGGGACTGCTTGAAAGCGC-3’ 
HHV-6 DRL 5’-CTTTCTCGCTGTGCCTCACGCTGTC-3’ 
Chromosome 11q primer (95) 5’-CAGACCTTGGAGGCACGGCCTTCG-3’ 
Chromosome 17p primer (95) 5’-AACATCGAATCCACGGATTGCTTTGTGTAC-3’ 
Chromosome 18q primer 5’-CTCATGTCCTCGGTCTCTTGCCTC-3’ 
Chromosome 17p probe (95) 5’-CCCAAGCAGGTTGAGAGGCTGAGG-3’ 
 
Generation of Recombinant Human Herpesvirus 6A BAC Virus Expressing GFP 
and Neomycin Resistance 
The generation of a recombinant HHV-6A (strain U1102) virus was accomplished 
through the cloning of GFP expression cassette and neomycin resistance between the 
two polyadenylation sites of ORF U53 and U54 (Fig. 7a).  The pBeloBAC11 plasmid 
(New England BioLabs, Ipswich, MA) with U53, U54, GFP, and neomycin resistance 
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gene was transfected into HEK-293 cells.  Cells were subsequently infected with wild 
type HHV-6A (wt-HHV-6A) to enable homologous recombination between vector ORF 
U53/U54 sequences with the genome of wt-HHV-6A (Fig. 8).   
The method of cloning the targeting pBeloBAC11 vector began by PCR 
amplification of ORF U53 (primers U53L and U53R) and ORF U54 (primers U54L and 
U54R) from HHV-6A DNA prepared from infected cells with primers containing restriction 
sites BamHI and SacII (Table 9).  In addition, the GFP expression cassette driven by the 
CMV immediate early gene promoter was amplified from pEGFP-N2 vector template (BD 
Biosciences Clontech) with primers GFP-N2-L and GFP-N2-R.  Next, the sub-cloning of 
ORF U53, ORF U54, and GFP was completed in pBluescript SK+ (Invitrogen™ Life 
Technologies™, Carlsbad, CA)  followed by sequencing to confirm the absence of PCR 
generated mutations. 
 
Table 9.  Oligonucleotides for generating Human Herpesvirus 6A BAC/GFP/Neor. 
 
The targeting vector was assembled by ligating fragments between the restriction 
sites BamHI and HindIII of pBeloBAC11 with T4 DNA ligase (Promega, Madison, WI) 
(Fig. 7b).  Ligated products were then transfected into ElectroMAX™ DH10B™ E. coli 
cells (Invitrogen™ Life Technologies™, Carlsbad, CA) through electroporation.  The size  
Oligonucleotide Name Sequence 
U53L 5'-GGCCCGCGGAGTAGTTCCGCGTCAGAATGC-3' 
U53R 5'-GGCGGATCCCATTCGTTTTATTGAACGCG-3' 
U54L 5'-GGCAAGCTTGCAATGGTTAAAAGTTGTTTTTTG-3' 
U54R 5-'GCGCCGCGGCTGCATACTTGCTACCGGAAC-3' 
GFP-N2-L 5'-CGCGGATCCATTAATAGTAATCAATTACGG-3' 
GFP-N2-R 5'-CGCGGATCCCGCCTTAAGATACATTGATGAG-3' 
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and orientation of ORF U53, ORF U54, GFP, and neomycin resistance cloned within 
pBeloBac11 was confirmed by restriction digestion and agarose gel electrophoresis.  
Positive clones were selected with 30 µg/ml kanamycin and plasmid was purified 
through QIAGEN® Plasmid Maxi Kit (QIAGEN Sciences, Germantown, MD) according 
manufactures instructions.  To further remove trace amounts of bacterial DNA, RNA, and 
proteins, U53/U54/GFP/Neo-pBeloBAC11 was subjected to CsCl/ethidium bromide 
density gradient.   
To permit homologous recombination between U53/U54/GFP/Neo-pBeloBAC11 
vector with ORF U53 and U54 encoded in the genome of wt-HHV-6A (Fig. 7b), the 
vector was first linearized through digestion with SacII.  Next, 5 µg of SacII digested 
U53/U54/GFP/Neo-pBeloBAC11 was transfected in a 6-well dish of HEK-293 at 70 % 
confluency with GenePORTER® Transfection Reagent (Genlantis, San Diego, CA) (Fig. 
8).  After 16 hrs post-transfection, HEK-293 cells were then infected with wt-HHV-6A 
(U1102) at ~1.0 multiplicity of infection (MOI).  Infected cultures were incubated for 5 – 
12 days to allow homologous recombination with vector and insertion of GFP and 
neomycin resistance gene into the HHV-6A genome (HHV-6AGFP).  Since infected HEK-
293 cells contain both wt-HHV-6A and HHV-6AGFP, cells were lysed through sonication 
or repeated freeze defrost cycles.  HHV-6AGFP virus was then titrated out by infecting 
Jjahn T-cell cultures with ~1 infectious unit per well in a 96 well plate.  HHV-6AGFP was 
expanded and progress of infection was monitored through GFP expression with Nikon 
TE300 inverted microscope equipped with SPOT RT-SE6 1.4MP Slider camera 
(Diagnostic Instrument. Inc.) and flow cytometric analysis. 
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Fig. 7.  Cloning of HHV-6A ORF U53 and U54 into pBeloBAC11 for generation of 
recombinant HHV6AGFP.  (a) Diagram of the HHV-6A genome with the location of ORF 
U53 and U54 highlighted.  The insertion of GFP/Neor/pBeloBAC11 occurs between the 
polyadenylation sites of ORF U53/U54 to prevent interruption of transcription and/or 
translation of those viral genes.  (b) Vector map of U53/U54/GFP/Neo-pBeloBAC11.  
The targeting vector was assembled by PCR amplify fragments of HHV-6A ORF 
U53/U54, as well as GFP and Neor from pEGFP-N2 vector (BD Biosciences Clontech).  
Fragments were then ligated between restriction sites BamHI and HindIII in pBeloBAC11 
(New England BioLabs, Ipswich, MA).  Restriction enzyme digestion of the SacII site 
between ORF U53 and U54 linearizes the vector in preparation of homologous 
recombination with HHV-6A genome (Fig. 8). 
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Fig. 8.  Strategy for construction of recombinant HHV-6A (U1102) virus expressing 
GFP (HHV-6AGFP).  As outlined in the scheme above, HHV-6AGFP was constructed by 
homologous recombination between B/GFP vector (U53/U54/GFP/Neo-pBeloBAC11) 
and the two polyadenylation signals of HHV-6A ORF U53 and U54 (85,981–86,034 bp)  
 
Partial and 454-Deep Sequencing of Germ-Line Integrated Human Herpesvirus 6 
Genome 
iHHV-6 sequences from PMBCs (Table 12) were amplified with primers spanning 
ORF U94 (fragment 141,267-143,197, primers U94L-1 and U94L-2; U94R-1 and U94R-
2) using 300 ng of genomic DNA with REDTaq DNA polymerase (Sigma-Aldrich) (Table 
10).  Cycling conditions were 95°C for 1 min, 66°C for 1 min, and then 72°C for 1.5 min 
for a total of 24 cycles.  Amplification of DR (fragment 421-1474, 151654-152707) with 
primers DR-1 and DR-2 and cycling 95°C for 1 min, 53°C for 1 min, and 72°C 1.5 min for 
a total of 24 cycles.  DNA bands were isolated from 0.8 % agarose gel and cloned into 
pCR®4-Topo® vector using the TOPO TA Cloning® Kit for Sequencing (Invitrogen, 
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Carlsbad, CA).  Clones (n=4) were then sequenced by the Molecular Biology core facility 
at the H. Lee Moffitt Cancer Center and Research Institute. 
454-sequencing of the iHHV-6A genome from Family-1/Sibling-2 was completed 
in collaboration with Rolf Renne and the University of Florida Interdisciplinary Center for 
Biotechnology Research. 
 
Table 10.  Oligonucleotides for amplifying and sequencing DR and ORF U94.  
Direct Repeat (DR) (U1102 421-1474, 151654-152707) and ORF U94 (U1102 141267-
143197). 
Oligonucleotide Name Sequence 
DR-1 5’-TGCCGCTTCAACTTCACCTT-3’ 
DR-2 5’-AGATGTGGAGAGAAACGCGA-3’ 
U94L-1 5’-TGTTCTTCTGCTAACTCGGACGCA-3’ 
U94L-2 5’-CAGTTCCAATGGGCGTGGACAAAT-3’ 
U94R-1 5’-ATCCACGCGTCTTCCGTGACTATT-3’ 
U94R-2 5’-TGTTCATGTCTTCCGGCGAAAGGT3-’ 
 
Single Telomere Length Analysis of iHHV-6 
Various methods have quantified the overall length of a population of telomeres 
(96).  However, Baird et al. has established a protocol to calculate the length of a 
telomere from a specific chromosome end (95, 97).  The single telomere length analysis 
(STELA) assay has successfully determined the length of telomeres from chromosomes 
XpYp, 2p, 11q, 12q, 17p, and 18q with use of primers specific to individual chromosome 
end.  Therefore, we have adapted the STELA assay to determine whether the telomere 
is extended beyond the left direct repeat (DRL) of iHHV-6A and iHHV-6B as well as 
quantify the overall telomere length of the integrated chromosome (Fig. 9).   
To begin, genomic DNA was isolated from iHHV-6A and iHHV-6B patients 
PBMCs (Table 12) and HHV-6A in vitro integrated HEK-293 cells (Table 2) with Wizard® 
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Genomic Purification Kit (Promega) or through proteinase-K digestion and 
chloroform/isoamyl alcohol (24:1) purification.  Next, the linker (Tellorette-2) containing a 
single TTAGGG repeat was ligated to the end of the telomere by incubating 60 – 150 ng 
of genomic DNA, 60 - 100 µM of oligonucleotide Telorette-2, and 4.5 U of T4 DNA ligase 
for 13 hrs at 35°C.  The ligation reaction was then purified through phenol 
chloroform/isoamyl alcohol (24:1) and resuspended in 15 µl TE.  Serial dilution of DNA 
was amplified with a high fidelity taq polymerase (Expand 20 kbPLUS PCR System, 
Roche), 25 µM linker annealing primer (Teltail-P1), 25 µM iHHV-6 primer (iHHV-6 
STELA-P2) (Table 11).  Cycling conditions were 92°C for 2 min, 27 cycles of 92°C for 15 
sec, 59°C for 30 sec, 68°C 13.5min or 18 min, and a final extension of 68°C for 7 min.  
Amplification products were separated through electrophoresis on a 0.8 % DNA agarose 
gel and Southern hybridized with [γ32P]-ATP-radiolabeled telomere oligonucleotide probe 
and PCR amplified (primers P3 + P4) HHV-6 DRL random primer [α32P]-dATP-
radiolabeled probe.   
Telomere length of iHHV-6 integrated chromosome was then calculated based 
upon the mean molecular weight of all bands co-hybridizing with telomere and HHV-6 
DRL probes. 
 
 
 
Fig. 9.  Diagram illustrates the strategy of single telomere length analysis (STELA) 
of iHHV-6.  To amplify the specific chromosome telomere (Tel) extended beyond the 
DRL of iHHV-6; a linker (Telorette-2) oligonucleotide is ligated to the end of the telomere.  
Amplification of the telomere is then preceded with primers P1 and P2.  
40 
 
Table 11.  Oligonucleotides for single telomere length analysis PCR and probe. 
Oligonucleotide Name Sequence 
Tellorette-2 (Linker) (97) 5'-TGCTCCGTGCATCTGGCATCTAACCCT-3' 
Teltail-P1 (97) 5'-TGCTCCGTGCATCTGGCATC-3' 
iHHV-6 STELA-P2 5’-AAGGATGGTAGGGTTTAGGGTCGAACC-3' 
iHHV-6 STELA-P3 5’-CCCTAACACTAATCCTCGCATCCGC-3’ 
iHHV-6 STELA-P4 5’-AAGGATGGTAGGGTTTAGGGTCGAACC-3’ 
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RESULTS 
 
AIM I.  To Determine whether the Human Herpesvirus 6A and 6B Genome 
Integrates into Chromosomes of in vitro Infected Cell Lines 
 
Two Novel in vitro Models Demonstrate HHV-6A Chromosome Integration 
Primary infection of HHV-6 leads to an increase in viral copies present in 
peripheral blood of children and subsequent decrease in viral copies during latency (5, 
13).  However, in a select number of patients including adults and children, there are 
high copies of HHV-6A and HHV-6B consistently detected in peripheral blood measuring 
greater than 1 million per ml or 1 copy of HHV-6 per cell (31, 33, 64, 65).  Through 
further evaluation of these patients with FISH analysis, it has been suggested that the 
genome of HHV-6 is integrated into the chromosome (28-32, 34, 98, 99).  However, the 
frequency of HHV-6 integration and whether integration is a product of infection remains 
unknown.  Therefore, in AIM I we developed two novel in vitro models of HHV-6A 
integration to determine the frequency with which new infection of naïve cell lines with 
HHV-6 leads to chromosomal integration, and whether this is the sole means by which 
HHV-6 achieves latency. 
 
 
 
42 
 
Single Cell Clones of Chromosome Integrated HHV-6A Human Embryonic 
Kidney-293 Cell Lines 
In our first model we set to determine if HHV-6A in vitro infection results in 
chromosome integration.  Since our preliminary experiments indicated that HEK-293 
cells do not produce any appreciable amount of virus in cultures reaching full confluency, 
we therefore expected this cell line to be a candidate to evaluate the in vitro integration 
of HHV-6A (Table 2).  We infected HEK-293 cells at 50 % confluency with HHV-6A 
(U1102) at 0.1 multiplicity of infection (MOI).  The cultures were incubated for five days.  
Then the infected HEK-293 cells were washed to remove extracellular virus, and single 
cells were introduced in each well of a 96 well plate.  The single cells in each well were 
then expanded and amongst these single cell clones, there were three populations.  The 
first population of single cell clones includes those that had reached cell senescence and 
stopped dividing most likely due to virus infection.  The second population of single cells 
included those that expanded at normal rate as uninfected controls.  However, the third 
population of cells appeared to have ceased cell division, but then proceeded to divide at 
a much slower rate than uninfected controls.  DNA was then extracted from these single 
cell clones and subjected to PCR for presence of the viral genome using ORF U94-
specific primers (Table 6) followed by agarose gel electrophoresis.  As show in Figure 
10a, 10 of the 22 HEK-293 cell clones were positive for ORF U94.  This indicates the 
successful infection and the presence of the HHV-6A genome within the HEK-293 single 
cell clones. 
To characterize the HEK-293 single cell clones for the presence of HHV-6A 
integrated into chromosomes, FISH was completed at the University of Minnesota (Fig. 
10b).  Three PCR-positive clones (clone 1, 2, and 3) and one PCR-negative clone (clone 
6) were studied for chromosome integration of HHV-6A by FISH.  Metaphase  
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Fig. 10.  Detection of the viral genome by PCR and fluorescent in situ 
hybridization (FISH) of HEK-293 cell clones latently infected with HHV-6A (U1102).  
(a) Genomic DNA was isolated from HHV-6A infected HEK-293 cell clones.  
Amplification of a 215 bp fragment representing ORF U94 was observed in five HHV-6A 
infected HEK-293 single cell clones.  (b) Representative FISH from three independent 
HEK-293 cell clones.  Hybridization was performed with HHV-6 cosmids pMF311-12 and 
pMF335-631 labeled with fluorescein (green) (84).  HEK-293/clone-1 had two 
independent chromosome-associated HHV-6A signals, while HEK-293/clone-2 and 
HEK-293/clone-3 only had one.  The HHV-6A-hybridizing chromosomes are labeled with 
white arrows and a higher magnification of the chromosomes are shown in red box.  
Metaphase chromosomes were stained with DAPI.  Total of 11 cells were observed for 
each clone. 
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chromosomes were obtained through culturing of the HEK-293 clones with colcemid 
which effectively inhibits the formation of the spindle apparatus through interruption of 
microtubules (90, 100).  HHV-6A in vitro chromosome integration was observed by 
fluorescein labeled HHV-6A (U1102 strain) pMF311-12 and PMF335-6 cosmid probes 
and metaphase chromosomes were counterstained with DAPI (84).  Analysis of HEK-
293/clone-2 and HEK-293/clone-3 identified one chromosome-associated HHV-6A 
signal, while HEK-293/clone-1 had two independent chromosomes associated with the 
HHV-6A genome (Fig. 10b).  Furthermore, association of the HHV-6A genome with 
chromosomes was identified at the termini of the long and short arm of chromosomes, 
which is in proximity of the telomere 
We could not identify the specific chromosomes into which HHV-6A had 
integrated in the HEK-293 cells using standard cytogenetic methods.  This was due to 
the aneuploidy and chromosomal rearrangements present in these cells.  Furthermore, 
the FISH assay cannot distinguish the non-covalent linkage of ccc episomes from 
chromosome integrated herpesviruses.  Therefore, we studied the in vitro integration of 
HHV-6A into HEK-293 single cell clones using inverse PCR (IPCR) (94).  Genomic DNA 
was first digested with the frequent cutter MboI, which cleaves methylated DNA.  After 
digestion and heat inactivation, we diluted the MboI digested DNA to 2 μg/ml, and ligated 
with 0.045 U/μl T4 DNA ligase for 14 hrs at 15°C.  The purpose of diluting digested DNA 
was to prevent ligation of unrelated fragments and select for self-circularization of the 
HHV-6A sequence with the adjacent chromosomal fragment.  We next amplified the 
ligated DNA using primers designed from the extreme right end (DRR) of the genome 
(Table 8), which enabled amplification of the unknown chromosome sequence that is 
fused with the viral genome (Fig. 30).  Southern blotting identified IPCR products that 
hybridized with a human telomere probe as well as an HHV-6 probe from the HHV-6A in 
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vitro integrated HEK-293 single cell clones (Fig. 11).  No hybridization was observed 
without ligation of the MboI fragments.  In summary, these experiments reveal that HHV-
6A can efficiently integrate into the telomeres of in vitro infected HEK-293 cells. 
 
 
Fig. 11.  Inverse PCR (IPCR) (94) analysis of DNA from HHV-6A in vitro infected 
HEK-293 clones.  Hypothesis: integration of HHV-6 occurs within the telomere of a 
human chromosome via homologous recombination with the TTAGGG perfect repeats 
within right direct repeat (DRR).  Genomic DNA from HEK-293 clones 1, 2, 3, and 6 were 
digested with MboI, diluted to prevent ligation of unrelated fragments, followed by self-
circularization of HHV-6 DRR with the adjacent chromosomal fragment.  IPCR products 
were analyzed by Southern blot hybridization with telomere oligonucleotide probe (left 
panel), and with HHV-6 IPCR probe (right panel).  Control IPCR was performed using 
DNA without ligation (unligated) and hybridization controls HHV-6A infected Jjhan as 
well as Jjhan (negative control).  
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Recombinant HHV-6A BAC Virus Expressing GFP and Neomycin 
Resistance 
The use of bacterial artificial chromosomes (BAC) vectors to clone the entire 
genome of herpesviruses has been instrumental in understanding the means by which 
viruses replicate, while knockout-mutants have characterized viral proteins.  To monitor 
HHV-6A infection, we constructed an HHV-6A recombinant virus (HHV-6AGFP) carrying 
the green fluorescent protein (GFP) and neomycin resistance (construction described in 
Figs. 5 and 6).  To accomplish this, we constructed a plasmid in which the GFP 
expression cassette is flanked by 2 kbp fragments of ORF U53 and ORF U54 cloned 
from HHV-6A strain U1102.  Then we infected several human monolayer cell lines and 
screened for those that supported lytic replication and in which transfection of the 
plasmid was efficient.  The most promising cell line was HEK-293 cells (101).  
Preliminary experiments indicated that HEK-293 cells produce infectious virus at low cell 
density/confluency.  To generate HHV-6AGFP recombinants, a HEK-293 monolayer was 
transfected with the ORF U53-GFP-ORF U54 BAC plasmid.  The following day, cells 
were seeded at about 10 % confluency and infected with 103 infectious units of HHV-6A 
(U1102).  After 6 days, we observed the characteristic cytopathic effect (ballooning, 
refractile giant cells).  The virus titer was determined to be 103 infectious units.   
Since infected HEK-293 cells contain both wt-HHV-6A and HHV-6AGFP, the 
potential recombinant virus was titrated out by infecting Jjhan T-cell cultures with about 
one infectious unit per a well in a 96-well plate.  In one culture, fluorescence microscopy 
showed a dramatic increase in the number of green fluorescent Jjhan cells from 7 to 37 
days post-infection (Fig. 12a).  We observed only a few very bright fluorescent large 
multinucleated cells, which were presumably producing infectious virus.  However, the 
majority of cells in the well displayed dimmer GFP expression. 
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Fig. 12.  Microscopic images and flow cytometry analysis of Jjhan cells infected 
with recombinant GFP expressing HHV-6A (HHV-6AGFP).  (a) Infection of Jjhan cells 
resulted in an increase number of green fluorescent cells from 7 to 37 days post-
infection as shown by fluorescent microscopy (100 X magnification).  (b) Flow cytometry 
analysis indicated that 60 % of Jjhan cells express GFP after 37 days post-infection with 
HHV-6AGFP.  (c) DNA from HHV-6AGFP and HHV-6A infected Jjhan cells as well as 
uninfected Jjhan and Molt3 cells were isolated.  PCR amplified ORF U53 with primers 
U53L and U53R produced a 2033 bp amplicon in HHV-6A and HHV-6AGFP infected cells. 
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To analyze the distribution of infected Jjhan cells, flow cytometry was used to 
examine the expression of GFP.  Overall GFP expression in HHV-6AGFP infected Jjhan 
cells was 60 % (Fig. 12b).  To next evaluate whether GFP fluorescence corresponded to 
production of HHV-6AGFP virions, we examined two hundred cells of the culture by 
transmission electron microscopy (TEM) in the Fred Hutchinson Cancer Center EM core 
laboratory for virus production.  Even after examining two hundred cells, no virions were 
observed.  The viral DNA was reproducibly detected by PCR, indicating the presence of 
the viral genome (Fig. 12c).  However, despite several attempts, we detected no free 
circular or linear viral genomes by the method of Gardella et al. (88).  Therefore, the data 
are consistent with the hypothesis that HHV-6AGFP established primarily latent infection 
in Jjhan cells cultured for over one month, and that latency did not involve the formation 
of viral episomes (Further evaluated in AIM 2 and AIM 3). 
Previous attempts by other laboratories to generate an infectious HHV-6 BAC 
cloned virus were unsuccessful (46, 102).  However, we were the first laboratory to 
successfully produce an infectious HHV-6A virus that expresses GFP and a selectable 
marker (33).  The reproducible cloning system was verified by Tang et al. in which they 
utilized E. coli mutagenous techniques to investigate the replication dependence of 
glycoprotein Q1 (103).  The knowledge gained from the adaptation of recombinant HHV-
6 viruses focuses future studies to comprehend the clinical balance of viral infection, 
latency/integration, and reactivation. 
 
The in vitro Infection of Human T-cell Lines with HHV-6A and HHV-6B Results in 
Telomere Integration 
Since we have demonstrated the in vitro integration of HHV-6A into HEK-293, we 
next wanted to determine if chromosome integration occurs in multiple cell types during 
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infection.  Specifically, we evaluated whether HHV-6A strain U1102 and HHV-6B strain 
Z29 can integrate into the telomeres of the T-cell lines Jjhan and Molt3.  These cells are 
routinely used to propagate HHV-6A and HHV-6B, yet we observed that despite 
supporting lytic infection, Jjhan and Molt3 cells often were not lysed and that many cells 
survived after the peak of productive infection. 
We hypothesized that in some of the infected cells, rather than productive 
infection leading to cell lysis, the virus had achieved latency through telomere 
integration.  To examine this hypothesis, we prepared DNA from cells at the peak of 
CPE, containing 103 infectious units/ml of virus.  We then amplified the putative viral 
genome-chromosome telomere junction using subtelomere based primers (2p, 11q, 17p, 
and 18q) and a primer derived near the right end of HHV-6 DRR (95, 97).  The primer to 
DRR and not DRL was utilized because preliminary results determined that HHV-6A in 
vivo integration occurs through the linkage of DRR with the telomere sequence directly 
adjacent to the end of the chromosome, while the remaining telomere is fused with DRL 
(Results further discussed in AIM 2, Figs. 19 and 23).  Furthermore, the human genome 
project has yet to fully sequence the ends of chromosomes due to their repetitive 
sequence and homology shared with other subtelomeres.  However, Baird et al. has 
successfully sequenced the ends of chromosomes (subtelomere) and has utilized 
primers 2p, 11q, and 17p to measure the length of telomeres of specific chromosomes 
through PCR (95, 97).  Consequently, Fig. 13 shows Southern hybridization of PCR 
amplified viral genome-chromosome telomere junction from HHV-6B infected Molt3 
cells. 
To sequence the viral genome-telomere junction of HHV-6B/HHV-6A integrated 
T-cell lines, we first cloned the PCR amplified fragments through pCR®4-TOPO® cloning 
system (TOPO TA Cloning® Kit for Sequencing, Invitrogen, Carlsbad, CA).  Following 
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electrical transformation of E. coli One Shot® TOP10 (Invitrogen, Carlsbad, CA), positive 
clones were identified by colony hybridization with [γ32P]-ATP-radiolabeled HHV-6 and 
telomere oligonucleotide probes.  Sequencing of clones confirmed the in vitro infection of 
Jjhan cells results in the HHV-6A genome covalently linked with the telomere of 
chromosomes 18q, 17p, and 11q (GenBank accession nos. GU784871 and GU784873) 
(Fig. 14).  Also, HHV-6B in vitro infection of Molt3 cells was found to integrate into 
telomere of chromosomes 18q, 11q, and 2p.  Therefore, the result of these experiments 
are consistent with the possibility that shortly after in vitro infection of Jjahn, Molt3, and 
HEK-293 cell lines, HHV-6A and HHV-6B can frequently integrate into the telomere 
region of chromosomes.  
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Fig. 13.  PCR amplification of virus-chromosome telomere junction from HHV-6B 
in vitro-infected Molt3 cells.  DNA from HHV-6B (Z29) infected Molt3 cells were 
subjected to amplification by PCR primers derived from HHV-6A DRR and subtelomere 
primers 2p, 11q, 12q, and 17p published by Baird et al (95, 97).  Subtelomere primer 
18q was designed based upon GenBank sequence information.  PCR products from 
virus-chromosome telomere junction were separated by electrophoresis and analyzed by 
Southern blot hybridization utilizing a 32P-labeled telomere oligonucleotide probe.  
Multiple band sizes are due to the variable number of telomere repeats between the DRR 
of HHV-6B and the chromosome (Fig. 14). 
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>HHV-6A/Jjhan chromosome 11q integration 
CAGACCTTGGAGGCACGGCCTTCGTTTGGGACAATTCGGGGCCGCATCGACGGTGAATAAAATCCTTCCTCTTTGCAGC
CCTGAATAATCAGGGTCAGAGATCAGTTAGGGTTAGGGTTAGGGTTAGGGTTGGGGTTGGGGTTGGGGTTGGGGTTGGG
GTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGG
TTAGGGTTAGGGTTAGCCGGTGGTTTCCTTTGGCACCGTGCCAGGCGACCGTGGGTCCCAGACGGTGGCACGTCGCGCG
CGATGTCGTTTTGAATTGTCTTCACGTCTCACCCCGGTATGCCCCATCTACGTACCCACCCGCGACTACCACATGGGTG
GGTTGTGCGTGTCTGTGTGTCTGCGTGTGTACGCGTCCGTGGTAGAAACGCGGTGACAACGGATTACGGAGGTGAATGT
TGCGGTGGTTGGGACGGGGAGGGAGTGAAGAGATGTTTCCCGTATAGGTGTTTTTGGAACGTGGTTTTTTTTTCTTACA
CTTGCCATGCTAGCGATCGCCCTCTGTCTTCGGTCCGCGTTACCGTGTCGTGTGTACTTCCGCATACTTTTGTCTCTGC
GCCTCGATACACCCCGTTGATTGGATGATCGCCACATGTGTATTGGACGTCACAGTCTGCTATTTTTTTCACTGTCTAT
TTTTAAACCTGTTGTCGTCTTCCCGCCAAGGCTATGTGTCTCCGCCTTTTCTTATATTTTTCTGACGCTGTTCGTTTTC
TACGTTCGCCTCCAATCCCGGACGCACCTCCTTTGTATGTTCACTCCTCCCACCCCCCGGGGTGCCTATATAAGAAGCG
AACGCGACGCGCTTTCAAGCAGTCCCGATCATG 
 
>HHV-6A/Jjhan chromosome 17p integration 
TAACATCGAATCCACGGAATGCTTGTGTACTTGGAAACTTAACAATGTGGTCTACAAATCCACAAATAAGATACATTTT
TACATTTACTGGAAGTTTAATTCCTAAGTAATGTCTTATAATTTCCCTCATCTAAGTCTGTCGTTTCATTCCATTTATT
CGTAAGTATAATATTGCTATTGGTATTGTTTAAGGTAGAATTTTCATAATTTGGTGTAGAGATTATTCATTCCTAGCAT
ATACATATAAAATGGAATGTTTGGCCAGGCACCCGGGCTCATACCTGTAACCCAAGCAGGTTGAGAGGCTGAGGAAGGG
TTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGCCGGTGGTTTCCTTTGGCACCGTGCCAGGCGACCGTGGG
TCCCAGACGGTGGCACGTCGCGCGCGATGTCGTTTTGAATTGTCTTCACGTCTCACCCCGGTATGCCCCATCTACGTAC
CCACCCGCGACTACCACATGGGTGGGTTGTGCGTGTCTGTGTGTCTGCGTGTGTACGCGTCCGTGGTAGAAACGCGGTG
ACAACGGATTACGGAGGTGAATGTTGCGGTGGTTGGGACGGGGAGGGAGTGAAGAGATGTTTCCCGTATAGGTGTTTTG
GAACGTGGTTTTTTTTTTCTTACACTGCCATGCTAGCGATCGCCCTCTGTCTTCGGTCCGCGTTACCGTGTCGTGTGTA
CTTCCGCATACTTTTGTCTTGCGCCTCGATACACCCCGTTGATTAGATGATCGCCACATGTGTATTGGACGTCACAGTC
TGCTATTTTTTTCACTGTCTATTTTTAAACCTGTTGTCGTCTTCCCGCCAAGGCTATGTGTCTCCGCCTTTTCTATATT
TTTCTGACGCTGTTCGTTTTCTACGTTCGCCTCCAATCCCGGACGCACCTCCTTTGTATGTTCACTCCTCCCACCCCCC
GGGGTGCCTATATAAGAAGCGAACGCGACGCGCTTTCAAGCAGTCCCGATC 
 
>HHV-6A/Jjhan chromosome 18q integration 
CTCATGTCCTCGGTCTCTTGCCTCGGCAAAGATTAGATTAGGGTTAGGGTTTGGGTTCGGGTCAGGGTTAGGGTTAGGG
GTTGGGGTTAGGGTTCGGGTTAGGGTCAGGGTTTGGGTTAGGGTTAGGGTTA---------------------------
GGGTTAGGGTTAGGGGTTGGGGTTAGGGTTCGGGTTAGGGTCAGGGTTTGGGTTAGGGTTAGGGTTAGGGTTAGGGTTA
GGGTTAGGGTTAGGGTTAGCCGGTGGTTTCCTTTGGCACCGTGCCAGGCGACCGTGGGTCCCAGACGGTGGCACGTCGC
GCGCGATGTCGTTTTGAATTGTCTTCACGTCTCACCCCGGTATGCCCCATCTACGTACCCACCCGCGACTACCACATGG
GTGGGTTGTGCGTGTCTGTGTGTCTGCGTGTGTACGCGTCCGTGGTAGAAACGCGGTGACAACGGATTACGGAGGTGAA
TGTTGCGGTGGTTGGGACGGGGAGGGAGTGAAGAGATGTTTCCCGTATAGGTGTTTTTGGAACGTGGTTTTTTTTTCTT
ACACTTGCCATGCTAGCGATCGCCCTCTGTCTTCGGTCCGCGTTACCGTGTCGTGTGTACTTCCGCATACTTTTGTCTC
TGCGCCTCGATACACCCCGTTGATTGGATGATCGCCACATGTGTATTGGACGTCACAGTCTGCTATTTTTTTCACTGTC
TATTTTTAAACCTGTTGTCGTCTTCCCGCCAAGGCTATGTGTCTCCGCCTTTTCTTATATTTTTCTGACGCTGTTCGTT
TTCTACGTTCGCCTCCAATCCCGGACGCACCTCCTTTGTATGTTCACTCCTCCCACCCCCCGGGGTGCCTATATAAGAA
GCGAACGCGACGCGCTTTCAAGCAGTCCCGATCTATG 
 
>HHV-6B/Jjhan chromosome 2p integration 
GAGCTGCGTTTTGCTGAGCACAGACCTGGGGGTCACCGTAAAGGTGGAGCAGCATTCCCCTAAGCACAGACGTTGGGGC
CACTGCCTGGCTTTGGGACAACTCGGGGCGCATCAACGGTGAATAAAATCTTTCCCGGTTGCAGCCGTGAATAATCAAG
GTCAGAGACCAGTTAGAGCGGTTCAGTGCGGAAAACGGGAAAGCAAAAGCCCCTCTGAATCCTGGGCAGCGAGATTCTC
CCAAGCTAAGGCGAGGGGCTGCATTAAAGGGTCCAGTTGCAGCATCGGAACGCAAATGCAGCATTCCTAATGCACACAT
GATACCCAAAATATAACACCCACGTTGCTCATGTGGTTAGGGTTAGGGTCAGGGTCGGGGTCGGGGTCGGGGTCAGGGT
CACGGTTAGGGGTTAAGTGTTAAGGGTTAGGGGTTAAGGGTTAGGGTTAGGGTAGGGTTAGG-----------------
AGGGTTAGGGTTAGGGTAGGGTTAGGGTTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTA
GGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAG
GGTTAGGGTTAGGGTTAGGGTTAGATTGCGCCAGCGGTTTCCCTTGGCGTCGTGCCAGGATAGCATGGGTCCGAGACGG
CGGCACGTCGCGCCCGATGCCGTTCCTCATTGTCTTCACATCTGCCCCCCGTATGCTCCCCGCCTGCCCACCCGCGACC
GCCATAGAGGTGGTGTGTGCGTGTCTGCGTGTCTGCGTGTGCACGCGTCTGTGGGAGAAACGCGGAGAAAAGGGATTAC
GGAGGGGGGTGTTGTGGTAGATGGGGTAGGGAGGGATGAAGGGATGTTTCCTTTGTTAGTATATTTCAGCGTTGTTTAT
TTTTTTTTCCTAGCTGCCATGCTAGGGGTCGGCCTTTGTCGTCGGTCCGCGTGACTGTCTGTCGCATGCACTTCCGTAT
ACTTTTTTTTTTTGCGCGCCGGCACGTCACGTCGATTGGATTGCTGCCACACGTGTATTCGATGGCATGGTCTCCTCTT
TTTTTTTTTCACTGTCTATCTCTGAACCTGTTATCGTCTTCCCGCCAAGGCTATGTGTCTCCGCCTTTCTTATTTTTTT
TACGCCGTTGATTTTCCGCGTTCGTCTCCAACCTCAGACCGACCTCGTGTGTATGTTGGCTCCTCCCACTCCCCGGGGC
GTCTATATAAAAGACGAATGTGGCGCGCTTTCAAGCAGTCCCGATCTATG 
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>HHV-6B/Jjhan chromosome 11q integration 
CAGACCTTGGAGGCACGGCCTTCGTTTGGGACAATTCGGGGCCGCATCGACGGTGAATAAAATCCTTCCTCTTTGCAGC
CCTGAATAATCAGGGTCAGAGATCAGTTAGGGTTAGGGTTGGGGTTGGGGTTGGGG-----------------------
AGGGTTTGGGTTGGGGTTGGGGTTGGGGTTGGGGTTGGGGTTGGGTTAGGGTTAGGGTTAGGGTTAGGTTAGGGTTAGG
GTTAGGGTTAGGGGTTAGGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAG
GGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGATTGCGCCAGCGGTTTCCCTTGGCGTCGTGC
CAGGATAGCATGGGTCCGAGACGGCGGCACGTCGCGCCCGATGCCGTTCCTCATTGTCTTCACATCTGCCCCCCGTATG
CTCCCCGCCTGCCCACCCGCGACTGCCATAGAGGTGGTGTGTGCGTGTCTGCGTGTCTGCGTGTGCACGCGTCTGTGGG
AGAAACGCGGAGAAAAGGGATTACGGAGGGGGGTGTTGTGGTAGATGGGGTAGGGAGGGATGAAGGGATGTTTCCTTTG
TTAGTATATTTCAGCGTTGTTTATTTTTTTTTCCTAGCTGCCATGCTAGGGGTCGGCCTTTGTCGTCGGTCCGCGTGAC
TGTCTGTCGCATGCACTTCCGTATACTTTTTTTTTTGCGCGCCGGCACGTCACGTCGATTGGATTGCTGCCACACGTGT
ATTCGATGGCATGGTCTCCTCTTTTTTTTTTTCACTGTCTATCTCTGAACCTGTTATCGTCTTCCCGCCAAGGCTATGT
GTCTCCGCCTTTCTTATTTTTTTTACGCCGTTGATTTTCCGCGTTCGTCTCCAACCTCAGACCGACCTCGTGTGTATGT
TGGCTCCTCCCACTCCCCGGGGTGTCTATATAAAAGACGAATGTGGCGCGCTTTCAAGCAGTCCCGATCTATG 
 
>HHV-6B/Jjhan chromosome 18q integration 
CTCATGTCCTCGGTCTCTTGCCTCGGCAAAGATTAGATTAGGGTTAGGGTTTGGGTTCGGGTCAGGGTTAGGGTTAGGG
TTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTCGGGTTCGGGTCAGGGTTAGGGTCAGGGTTAGGGTTAGGGTTAGGGT
TAGGGTT------------------------------------------------------------------------
AGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTCGGGTTCGGGTCAGGGTTAGGGTCAGGGTTA
GGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTGGGTTAGG
GTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGG
TTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGATTGCGCCAGCGGTTTCCCTTGGCGTCGTGCCA
GGATAGCATGGGTCCGAGACGGCGGCACGTCGCGCCCGATGCCGTTCCTCATTGTCTTCACATCTGCCCCCCGTATGCT
CCCCGCCTGCCCACCCGCGACTGCCATAGAGGTGGTGTGTGCGTGTCTGCGTGTCTGCGTGTGCACGCGTCTGTGGGAG
AAACGCGGGGAAAAGGGATTACGGAGGGGGGTGTTGTGGTAGATGGGGTAGGGAGGGATGAAGGGATGTTTCCTTTGTT
AGTATATTTCAGCGTTGTTTATTTTTTTTTCCTAGCTGCCATGCTAGGGGTCGGCCTTTGTCGTCGGTCCGCGTGACTG
TCTGTCGCATGCACTTCCGTATACTTTTTTTTTTTGCGCGCCGGCACGTCACGTCGATTGGATTGCTGCCACACGTGTA
TTCGATGGCATGGTCTCCTCTTTTTTTTTTTTCACTGTCTATCTCTGAACCTGTTATCGTCTTCCCGCCAAGGCTATGT
GTCTCCGCCTTTCTTATTTTTTTTACGCCGTTGATTTTCCGCGTTCGTCTCCAACCTCAGACCGACCTCGTGTGTATGT
TGGCTCCTCCCACTCCCCGGGGTGTCTATATAAAAGACGAATGTGGCGCGCTTTCAAGCAGTCCCGATCTATG  
 
Fig. 14.  Sequencing of virus-chromosome telomere junction from HHV-6A 
infected Jjhan cells and HHV-6B infected Molt3 cells.  DNA from HHV-6A (U1102) 
infected Jjhan cells and HHV-6B (Z29) infected Molt3 cells were subjected to 
amplification by PCR primers derived from HHV-6A DRR and subtelomere primers 2p, 
11q, and 17p published by Baird et al. (95, 97).  Subtelomere primer 18q was designed 
based upon GenBank sequence information.  After cloning and sequencing of PCR 
products data was subjected to GenBank nucleotide sequence analysis.  Virus-
chromosome telomere junction is indicated: telomere TTAGGG repeats underlined and 
bold, HHV-6 DRR text is red, and chromosome subtelomere text is blue.  
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AIM II.  To Determine that Human Herpesvirus 6A and 6B Genome Integrates into 
the Telomeres of Patients through Germ-Line Transmission 
 
The HHV-6A and HHV-6B Genome Integrates into Telomeres of in vivo Infected T-
cells during Latency 
Results from AIM 1 illustrate the in vitro infection of human T-cell lines as well as 
HEK-293 cells with HHV-6A and HHV-6B results in the integration of the viral genome 
into the telomere of chromosomes.  Studies have also suggested that individuals can 
harbor the HHV-6A or HHV-6B genome integrated into their chromosomes (28-31, 34, 
98, 99) and may be vertically transmitted in the germ line (32).  However, evidence of in 
vivo integration is based primarily on fluorescent labeling of chromosomes with HHV-6 
probes through FISH.  This assay cannot distinguish non-covalent linkage of viral 
episomes from chromosome integration and nor can establish the specific site of viral 
integration.  Therefore we sought to determine whether the in vivo integration of HHV-6A 
and HHV-6B actually occurs and define the specific site of viral integration.   
Several individuals were identified with neurological symptoms including CNS 
dysfunction, ataxia, and chronic fatigue (Table 12).  Family members of those individuals 
also shared the same symptoms or were asymptomatic.  A total of 13 patients from 4 
different families living in various regions around the world were enrolled in this study.  
Peripheral blood was isolated from each family member and quantitative real time PCR 
identified more than one family member, including a parent and at least one child, had 
an unusually high copy numbers of HHV-6 DNA.  The copy numbers from individuals 
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from 4 different families were at least one million copies of HHV-6 per ml of peripheral 
blood (Table 12).  However, Kondo et al. determined the copy number during the peak 
of primary infection was only 637 ± 273 in 104 monocytes/macrophages and 115 ± 42 in 
104 CD4+ T-cells (10).  Therefore, the elevated copy numbers consistently detected in 
patients of this study suggests chromosome integration of the viral genome. 
To investigate the possibility that HHV-6A/HHV-6B had integrated into the family 
members’ chromosomes, we first performed fluorescence in situ hybridization (FISH) on 
T-cell cultures derived from peripheral blood. The experiments were performed in two 
independent laboratories (University of Minnesota, Minneapolis, MN and Children’s 
Cancer Research Institute, Vienna, Austria).  Each laboratory was blind to knowledge of 
the individual and family membership from which each specimen had been obtained.  In 
each experiment, HHV-6-specific fluorescence was detected in association with the 
telomeric regions of chromosomes (Table 12 and Fig. 15).  The specific chromosome 
was identified by co-hybridization with viral and chromosome specific probes.  HHV-6-
specific FISH signal was detected in chromosomes 17p13.3, 18q23, and 22q13.3, in the 
three families studied with FISH.  In each of these family members with integrated HHV-
6, the chromosome of integration was identical between both parent and children, 
suggesting vertical transmission through the germ-line [inherited HHV-6 (iHHV-6)].  
Furthermore, iHHV-6 and telomere FISH signals overlapped which signifies 
chromosome integration occurs specifically at the telomere. 
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Fig. 15.  Fluorescent in situ hybridization (FISH) of metaphase chromosomes from 
T-lymphocytes of family members.  PBMCs were stimulated for 72 hrs with 20 ng/ml 
PHA then cultured in RPMI 1640 medium containing 50 U/ml IL-2 and 10 % FCS.  
Metaphase chromosomes were generated according to standard cytogenic protocol 
(90), stained with DAPI and hybridized with various probes as follows; (a) FITC-
conjugated HHV-6A (U1102 strain) cosmid probes pMF311-2 and pMF335-6 (green) 
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(84) and cy5-conjugated telomere peptide nucleic acid (PNA) probe (red) 
(DakoCytomation).  The viral genome was present in the same chromosome of the 
corresponding parents and siblings suggesting germ line transmission (32, 33): Family-1 
chromosome 18q23; Family-2 chromosome 17p13.3; and Family-3 chromosome 
22q13.3.  Lower right hand corner of each figure contains magnification of the 
chromosome with integrated iHHV-6l DNA.  (b) Representative FISH from members of 
Families 1-3.  Hybridization with FITC-conjugated HHV-6A (U1102 strain) cosmid probes 
pMF311-2 and pMF335-6 (84).  (c) cy5-conjugated BCL2 probe (Chromosome 18) (red), 
FITC-conjugated chromosome 17 centromere probe (green), and cy5 and FITC-
conjugated EWSR1 probe (Chromosome 22) (dual labeled-red and green bottom row) 
(Vysis). 
 
To investigate whether the FISH method truly detects integration of iHHV-6 into 
the chromosome of human telomeres rather than an association of the telomere with 
episomal viral DNA, we analyzed T-cells from members of Family-1 with the method of 
Gardella et al. (88).  This method utilizes a vertical agarose gel capable of distinguishing 
cellular genomic DNA from covalently closed circular DNA (episomes), and replicating 
linear viral DNA (Fig. 4).  This occurs through the gently release of the DNA by in situ 
lysis of 1×106 PBMCs or T-cells within the loading well of the vertical agarose gel 
followed by the application of an electric current.  Southern hybridization with an HHV-6A 
cosmid probe (84) confirmed the association of the viral genome with cellular DNA 
located in the loading well of these gels (Fig. 16).  No circular episomal and unit length 
linear viral DNA was detected in these experiments which indicates that chromosome 
integration is potentially a novel method in which a human herpesvirus can establish 
latency.  As a control, the blot was stripped and hybridized with a mitochondrion 
oligonucleotide probe to illustrate successful cell lysis and separation of high molecular 
weight mitochondrion DNA still remaining in the loading well from the circular and linear 
forms.  
To further validate the Gardella gel results, T-cells from member of Families 1, 2, 
and 3 were immortalized using Herpesvirus saimiri (HVS) strain C484 and then applied  
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Fig. 16.  The vertical agarose gel technique identifies HHV-6 present in the host 
genomic fraction of Family-1 T-cells.  One million T-cells isolated from Family-1 
members, control uninfected PBMCs, and HHV-6 positive Katata cell line (HHV-6B 
integrated Burkitt’s lymphoma cell line) (83).  Cells were loaded on a vertical agarose gel 
and analyzed for episomal, linear, or integrated DNA by the method of Gardella et al. 
(88).  Southern hybridization with HHV-6A cosmid probe (Left panel) (84).  Blot was 
stripped and hybridized with mitochondrion oligonucleotide probe (Right panel) (89).  
 
 
 
 
 
60 
 
 
 
 
 
Fig. 17.  Analysis of HVS immortalized T-cells from iHHV-6 family members with 
the vertical agarose gel technique.  T-cells isolated from family members immortalized 
with H. saimiri (HVS) strain C484 were subjected to vertical agarose gel technique of 
Gardella et al. (88).  Agarose gel was stained with ethidum bromide (left panel) and 
southern hybridization with HHV-6A cosmid probe (middle panel) (84) illustrates viral 
integration into the genome.  Proper cell lysis and separation of linear and circular 
fractions was evaluated by striping blot and hybridized with H. saimiri cosmid probe 
(right panel) (86). 
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to the Gardella gel.  Southern hybridization with HHV-6A cosmid (84) probe detected 
viral signal only within the genomic fraction (loading well) of the Gardella gel (Fig. 17), 
which is consistent with results in Fig. 16.  Hybridization of the same Southern blot with 
HVS probe detected both circular episomal and replicating linear HVS DNA, confirming 
proper release of herpesvirus DNA in the gel as well as the sensitivity of this assay (Fig. 
17).  Therefore, integration of iHHV-6 genome into the chromosome of Family-1, 2, and 
3 members occurs during latency, while episome and replicating linear viral DNA was 
not detected. 
In Aim 1, we utilized Southern hybridization coupled with IPCR to establish that 
HHV-6A in vitro integration of HEK-293 cells occurs at the telomeres (Fig. 11).  
Likewise, IPCR experiments were also performed using DNA samples isolated from 
PBMCs from members of Family-1.  Briefly, genomic DNA was digested with the 
frequent cutter MboI, which cleaves methylated DNA (Fig. 5).  After digestion and heat 
inactivation, we diluted the DNA to 2 μg/ml and incubated with T4-ligase for 16 hrs at 
15°C.  The purpose of diluting digested DNA was to prevent ligation of unrelated 
fragments and select for self-circularization of the iHHV-6 sequence with the adjacent 
chromosomal fragment.  We next amplified the ligated DNA using primers designed from 
the extreme right end (DRR) of the genome (Table 8), which enabled amplification of the 
unknown chromosome sequence that is fused with the viral genome.  Southern 
hybridization of IPCR products were shown to hybridize with the HHV-6 and telomere 
specific probe (Fig. 18).  It is noteworthy that the IPCR products were identical in size 
from iHHV-6A positive Family-1 members. 
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Fig. 18.  Inverse PCR (IPCR) analysis of iHHV-6A infected T-cells from Family-1.  
Genomic DNA isolated from Family-1 T-cells were digested with MboI and diluted to 
select for ligation of unrelated fragments. PCR amplification of HHV-6-chromosome 
telomere fragments were then achieved through HHV-6 primers IPCR-1 and IPCR-2 
(Table 7).  Co-hybridization of HHV-6 IPCR (right panel) and telomere (left panel) 
oligonucleotide probe via Southern hybridization detects viral integration into human 
telomeres.  Mother’s genome was negative control for IPCR (Table 12). 
 
Covalent Linkage of the HHV-6 Genome with the Subtelomere of Chromosomes is  
Mediated through the Viral Telomere Repeats Encoded in DRR 
To build upon the experiments in the previous section, we next wanted to 
definitely illustrate the in vivo integration of HHV-6A and HHV-6B into the telomeres of 
chromosomes by directly amplifying and sequencing the site of integration.  The HHV-6A 
and HHV-6B genomes encode a perfect TTAGGG telomere repeat array at the right end 
direct repeat (DRR) and an imperfect TTAGGG repeat at the end of left end direct repeat 
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(DRL) (Fig. 1) (3, 4, 104).  We established a working hypothesis that HHV-6A and HHV-
6B integrates into telomeres via homologous recombination. 
To amplify the putative viral-chromosomal DNA junction, we created a primer pair 
homologous to the DRL and DRR of the viral genome, as well as a primer to the 
subtelomere of chromosome 17p (Figs. 6 and 19a).  The subtelomere is the 
chromosomal region immediately adjacent to the TTAGGG telomere repeat array.  T-cell 
DNA isolated from Family-2 members were analyzed in these experiments since FISH 
had identified the integration of HHV-6A into chromosome 17p13.3 (Fig. 15), and the 
sequence of telomere-subtelomere junction of chromosome 17p is known (95).  
Amplification with the primer pair designed from DRR and 17p subtelomere successfully 
amplified the viral-cellular junction as determined by co-Southern hybridization with 
HHV-6 DRR, telomere, and chromosome 17p oligonucleotide probes (Fig. 19b).  
Furthermore, the absence of amplification with a primer derived from DRL confirmed the 
integration of HHV-6A into human subtelomere is mediated through the perfect 
TTAGGG found at the end of DRR.   
To conclusively illustrate the HHV-6A DRR-subtelomere-chromosome junction, 
the predominant 1.5 kbp amplicon was excised from the gel and cloned into pCR®4-
Topo® vector using the TOPO TA Cloning® Kit for Sequencing (Invitrogen, Carlsbad, 
CA).  E. coli One Shot® TOP10 (Invitrogen, Carlsbad, CA) was transformed through 
electroporation and cultured with LB plates (30 µgl/ml kanamycin).  Clones containing 
the HHV-6A DRR-subtelomere-chromosome junction were determined through colony 
hybridization with radiolabeled telomere, HHV-6, and chromosome 17p oligonucleotide 
probes (Table 8).  Plasmid DNA from positive clones was isolated with QIAprep® Spin 
Miniprep Kit (Qiagen, MD) and Sanger sequencing was completed by the Molecular 
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Fig. 19.  Chromosome 17p subtelomere-specific PCR analysis of Family-2 
members.  (a) The putative HHV-6A-chromosome 17p junction.  Arrows indicate 
position of primers derived from the direct repeat left (DRL) and right (DRR) of the viral 
genome (Unique = U) and to chromosome 17p subtelomere (95).  (b) Genomic 
DNA subjected to amplification: Family-2 Mother and Sibling, HHV-6A infected, and 
uninfected Jjhan cells.  PCR amplicons were separated by electrophoresis and analyzed 
by Southern blotting using 32P-labelled oligonucleotide probes as indicated at the bottom 
of each panel.  Co-hybridization of a 1.5 kbp fragment with all three probes illustrates the 
chromosome telomere joining with HHV-6A DRR.  (c) The predominant 1.5 kbp amplicon 
from Family-2/Mother was cloned (n=3) and sequenced.  Genbank homology search 
confirmed the presence of chromosome subtelomere 17p sequence (top) joined with 
TTAGGG telomere repeats (red and underlined), and HHV-6A DRR sequence (bottom).  
GenBank accession no. GU784872. 
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Biology core facility at H. Lee Moffitt Cancer Center and Research Institute using T3 and 
T7 primers.  Sequencing results indentified the HHV-6A DRR covalently linked with the 
subtelomere sequence of chromosome 17p from members of Family-2 (Fig. 19c).  The 
integration site contained 5 TTAGGG repeats, and integration resulted in the loss of 79 
nucleotides from the far right end (DRR) the iHHV-6A genome (GenBank accession no. 
GU784872).  This observation is in agreement with other publications that have found 
variability in the number of telomere repeats at the end of HHV-6 DRR and DRL (45, 99). 
 
The Chromosome Telomere is Covalently Linked to the DRL of iHHV-6 Genome 
Results in the previous section illustrate the telomere integration of iHHV-6 
occurs through recombination with the perfect telomere repeats encoded in the DRR 
(Fig. 19).  Therefore, we sought to further characterize the genomic structure of iHHV-6.  
Specifically, we wanted to determine if the DRL of iHHV-6 was conserved with the 
integrated genome and whether the tandem array of telomere repeats [(TTAGGG)n] at 
the end of the chromosomes was extend beyond the DRL (Fig. 20). 
 
 
Fig. 20.  Analysis of the genome conformation of chromosome integrated iHHV-6.  
Results in Fig. 19 illustrate the DRR of iHHV-6 fused with the chromosome subtelomere.  
However, it’s unknown whether homologous recombination occurs with the DRL (a) 
perfect or (b) imperfect telomere repeats.  Therefore there is a possibility the DRL could 
be lost from the integrated genome during the process of integration. 
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Experiments by Frenkel et al. has demonstrated the deletion of DR1 through the 
first exon of DR6 from a laboratory strain of HHV-6A (U1102) was dispensable for in 
vitro replication (47, 102).  The deletion of DR was found during the process of cloning 
the linear concatemer form of the virus during lytic replication.  Therefore, we have 
developed two PCR based assays to determine if the DRL of iHHV-6 was conserved with 
the integrated genome of patients in this study (Table 12). 
In the first experiment, the DRL was successfully amplified from Family-1 
members’ genomic DNA (Fig. 21).  Following Southern hybridization with telomere 
specific oligonucleotide probe, we identified variability in the predicted molecular weight 
of the amplified fragments.  The variable number of telomere repeats between DR and U 
has been previously characterized in clinical HHV-6 isolates (33, 45).  
To confirm the results in the previous experiment, we evaluated the DRL in a 
second group of patients with iHHV-6 and utilized a second primer set in combination 
with restriction enzyme digestion (Fig. 22a).  The PCR amplified DRL fragment has two 
DraI restriction sites that lead to the expected fragment sizes of 1027, 217, 186 bp 
according to the HHV-6A genome (strain U1102) (4).  Similar to the results in Fig. 21, 
the DRL was present in the iHHV-6 genome of all patients evaluated with PCR 
amplification and DraI digestion (Fig. 22b).   
Since we have illustrated the conservation of the DRL from iHHV-6, we next 
wanted to determine whether the tandem array of telomere repeats [(TTAGGG)n] at the 
end of the chromosome was extend beyond the DRL.  Various methods have quantified 
the overall length of a population of telomeres (96).  However, Baird et al. has 
established a protocol to calculate the length of a telomere from a specific chromosome 
end (95, 97).  The single telomere length analysis (STELA) assay has successfully 
determined the length of telomeres from chromosomes XpYp, 2p, 11q, 12q, 17p, and  
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Fig. 21.  Amplification of the DRL from chromosome integrated iHHV-6.  (a) 
Diagram for the amplification of DRL in which primer 1 (P1) binds to region inside of DRL 
and primer 2 (P2) binds within the U region of iHHV-6.  (b) Amplification of DRL from 
members of Family-1 results in the predicted size of 1,198 bp (HHV-6A U1102) as 
shown in the ethidium bromide (Etbr) staining (left panel).  Southern hybridization with 
telomere oligonucleotide probe (right panel).  Controls: HHV-6A (U1102) positive control 
while Family-1/Mother and Jjhan were negative controls. 
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Fig. 22.  Amplification and restriction digestion of the DRL from chromosome 
integrated iHHV-6.  (a) Diagram for the amplification of DRL in which primer 3 (P3) 
binds to region inside of DRL and primer 4 (P4) binds within the UL of iHHV-6.  DraI 
restriction sites are indicated by red arrows.  (b) Amplification and restriction digestion 
with DraI results in the predicted 1027, 217, 186 bp (HHV-6A U1102) as shown in the 
ethidium bromide (Etbr) staining (left panel).  Southern hybridization with HHV-6 DRL 
oligonucleotide probe hybridizes with DRL 1027 bp band (right panel).  Controls: HHV-6A 
(U1102) positive control and Jjhan negtaive control. 
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18q with use of primers specific to individual chromosome ends.  Therefore, we have 
adapted the STELA assay to determine whether the telomere is extended beyond the 
left direct repeat (DRL) of iHHV-6A and iHHV-6B as well as quantify the overall telomere 
length of the integrated chromosome (Fig. 20).   
To begin, genomic DNA was isolated from iHHV-6A and iHHV-6B patients (Table 
12) with Wizard® Genomic Purification Kit (Promega).  Next, the linker (Tellorette-2) 
containing a single TTAGGG repeat was ligated to the end of the telomere by incubating 
60 – 150 ng of genomic DNA with T4 ligase for 13 hrs at 35C (Fig. 23a).  The reaction 
was then purified through phenonl chloroform/isoamyl alcohol (24:1) and resuspended in 
TE.  Serial dilution of linker-DNA was amplified with a high fidelity taq polymerase 
(Expand 20 kbPLUS PCR System, Roche), linker annealing primer (Teltail-P1), and iHHV-
6 primer (P2) (Fig. 23a).  The specific amplification of telomere sequences at the end of 
DRL was indentified through southern hybridization with [γ32P]-ATP-radiolabeled 
telomere oligonucleotide probe (Fig. 23bc).   
To confirm the specific amplification of telomere sequences extended beyond  
DRL of iHHV-6, the nitrocellulose blot was stripped and re-hybridized with PCR amplified 
iHHV-6A DRL random primer [α32P]-dATP-radiolabeled probe.  Co-hybridization of 
telomere and DRL probes confirmed amplification of adjoining chromosome telomere 
with the DRL of iHHV-6 (Fig. 20a).  The heterogeneity of amplified telomere fragments 
has also been previously observed in non-iHHV-6 integrated human somatic cells (95, 
97).  Furthermore, the specific telomere length of iHHV-6A integrated chromosome 17p 
of Family-1/Sibling-2 PBMCs was 5,158 bp.  This was calculated by determining the 
mean molecular weight of all bands co-hybridizing with telomere and iHHV-6A DRL 
radiolabeled probes from eight different PCR reactions. 
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Fig. 23.  Single telomere length analysis of iHHV-6 integrated PBMCs.  (a) Diagram 
illustrating the strategy of single telomere length analysis (STELA) of iHHV-6.  To amplify 
the specific chromosome telomere (Tel) extended beyond the DRL of iHHV-6; a linker 
(Telorette-2) oligonucleotide is ligated to the end of the telomere.  Amplification of the 
telomere is then preceded with primers P1 and P2.  Serial dilution of (b) 150 ng and (c) 
60 ng of DNA (EcoRI digested +/- for DNA solubilization) isolated from Family-1/Sibling-
2 (F1/S2) PBMCs was amplified with STELA primers.  The specific telomere length of 
iHHV-6A integrated chromosome 17p of Family-1/Sibling-2 PBMCs was 5,158 bp, while 
the amplified range was 12,307 bp to 1,300 bp.   
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HHV-6 Maintains its Latent Genome through Integration into Telomeres of 
Chromosomes in the Absence of Covalently Closed Viral Episomes 
Following infection, the genome of herpesviruses circularizes and the genome 
replicates through rolling-circle replication facilitated by the viral DNA polymerase (26, 
27).  Replication leads to the formation of concatemers of linear viral genomes linked in 
a head-to-tail conformation.  The viral concatemer is subsequently cleaved to give rise to 
single copies of the full length viral genome.  However during latency, the genome of 
herpesviruses remains as a nuclear circular episome, while the cellular DNA polymerase 
and latency-associated viral genes promote replication of the viral genome without 
formation of infectious virus (1, 26, 27).  Moreover, the viral latency genes EBNA1 and 
LANA promote the association of EBV and KSHV episomes with chromosomes via 
protein-protein interactions (35, 36).  This ensures each infected cell obtains multiple 
copies of the viral episome during cell division.  Therefore, the central dogma of 
herpesvirus replication is that the viral genome establishes latency as a nuclear circular 
episome and reactivation occurs through rolling-circle DNA replication (1, 26, 27). 
We previously utilized the Gardella gel assay (88) to demonstrate the in vivo 
integration of iHHV-6A into the chromosomes of members from Family-1 during latency 
(Fig. 16).  Furthermore, even after utilizing P32 radiolabeled HHV-6A cosmid probes (84), 
the Gardella gel assay did not detect the presences of HHV-6 episomes.  Therefore, we 
looked for small numbers of episomes that might not have been detectable by the 
Gardella gel assay (88). 
Genomic DNA was isolated from HHV-6A integrated HEK-293 cells (Table 2), 
and HVS immortalized iHHV-6A integrated T-cells from a member of Family-1 and 2 
(Fig. 17).  We next subjected these cells to CsCl/ethidium bromide gradient 
ultracentrifugation to isolate the viral episome from the cccDNA fraction and the 
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Fig. 24.  PCR amplification fails to detect HHV-6 DNA in episomal fractions of 
CsCl/ethidium bromide (EtBr) gradients.  To search for covalently linked circular viral 
episomes by a method more sensitive than the method of Gardella (88), 50 µg DNA from 
two latently infected HEK-293 clones, T-cells from Family-2/Mother, and T-cells from 
Family-1/Sibling-2 immortalized with HVS strain C484 were subjected to CsCl/EtBr 
gradient ultracentrifugation for two days (CsCl density 1.55 g/ml, 10 µg/ml EtBr, VTI 65 
rotor 40K rpm).  After centrifugation fractions were collected, linear and episomal (ccc) 
DNA identified by agarose electrophoresis.  Salt and EtBr were removed from combined 
linear and episomal ccc fractions and were subjected to PCR based amplification using 
primers to (a) HHV-6 ORF-U94 and mitochondrial cytochrome c oxidase (positive 
episomal control), (b) ORF U94 (HHV-6 genome) and beta actin  (positive chromosome 
control), and (c) HHV-6 ORF-U94, C484 (Stp), and cytochrome c oxidase (positive 
episomal control).  ccc stands for covalently closed circular episomal fraction. 
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chromosome integrated iHHV-6A from the linear fraction.  Fractions were subjected to 
PCR amplification with primers to beta actin and cytochrome C oxidase (mitochondrion 
genome) to identify the linear DNA and cccDNA fractions respectively (91, 92).  PCR 
amplification of ORF U94 (HHV-6) was then utilized to determine if the viral genome was 
integrated or a circular episome during latency.  Following CsCl/ethidium bromide 
gradient and PCR amplification, iHHV-6 DNA was detected only in the linear fraction, 
and was completely absent from the episomal (ccc) DNA fraction in both patient T-cells 
and HEK-293 cells (Fig. 24ab).  
 Since our PCR assay can detect as few as 1-5 molecules, the CsCl/ethidium 
bromide gradient ultracentrifugation experiment confirmed that the HHV-6 episome 
cannot be detected even by a highly sensitive method.  The amplification of 
mitochondrial sequence in the linear fraction is expected since replicating and relaxed 
mitochondrial episomes band together.  Furthermore, the detection of HVS episomes in 
immortalized iHHV-6A integrated T-cells demonstrate the sensitivity of this assay (Fig. 
24c).  
 
The Genome Sequence of Germ-Line Integrated HHV-6 from Patient T-cells is 
Divergent from HHV-6A (strain U1102) and HHV-6B (strain Z29) 
To investigate whether the iHHV-6 genome integrated in chromosomes of 
Family-1 is the same among family members and to determine the degree of similarity to 
HHV-6A (strain U1102) and HHV-6B (strain Z29), Southern hybridization of EcoRI 
digested genomic DNA was performed (Fig. 25).  Hybridization using a mixture of HHV-
6A (U1102 strain) cosmids (84) representing about 80% of the viral genome, revealed 
that the banding pattern was indistinguishable among iHHV-6 positive members of  
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Fig. 25.  EcoRI restriction site analysis of integrated iHHV-6A in Family-1 T-cells. 
Total genomic DNA was isolated from iHHV-6 integrated Family-1 members’ PBMCs, 
HHV-6A (U1102 strain) infected Jjhan cells, HHV-6B (Z29 strain) infected Molt3 cells, 
and uninfected PBMCs with Wizard Genomic DNA Purification Kit (Promega) according 
to manufacturer’s protocol.  5 μg of genomic DNA was digested with 24 U of EcoRI 
(Promega) and separated on 0.8% horizontal agarose gel.  Southern hybridization was 
completed with HHV-6A (U1102) cosmid (84) probe mixture. 
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Family-1.  However the pattern of the integrated viral DNA was significantly different 
from prototype HHV-6A (U1102) or HHV-6B (Z29).   
To evaluate the degree of variation between Family-1 and Family-2 integrated 
iHHV-6 from the prototypical HHV-6A and HHV-6B strains, ORF U94 (141267-143197 
bp) and DR (421-1474 bp, 151654-152707 bp) were amplified by PCR and cloned into 
the pCR®4-TOPO® vector (Invitrogen).  Sequencing was completed with primers T7 and 
T3 by the Molecular Biology core facility at the H. Lee Moffitt Cancer Center and 
Research Institute.  The viral sequences from various family members were identical as 
illustrated by the multiple sequence alignment (Fig. A1).  However, the sequence DR 
shared 96% identity with HHV-6A and 89% identity with HHV-6B (Table 12).  DNA 
sequences of the rep gene ORF U94 were more conserved; 98% identity with HHV-6A 
and 95% identity with HHV-6B.  It is noteworthy that chromosomal integrated iHHV-6 
sequences obtained from Family-1 and Family-2 were more closely related to each other 
than to HHV-6A and HHV-6B alone.  Therefore, the similar viral sequences (Fig. A1 and 
Table 12) and identical sites of chromosome integration (Fig. 15 and Table 12) between 
family members confirms vertical transmission of the iHHV-6 genome through the germ-
line. 
In a study completed by Rapp et al.(105), sequences of the ORF U94 gene 
shared remarkable conservation among isolates of HHV-6A (U1102 strain-99.4% 
identity) and HHV-6B (Z29 strain-99.7% identity) among 17 isolates from three different 
geographical locations.  In contrast, our work has found only 98% sequence identity 
between ORF U94 from the integrated iHHV-6 genome in two families (Table 12).   
Since we have completed partial sequencing of the iHHV-6 genome (ORF U94 
and DR), we now sought to determine the complete genome sequence of the reactivated 
iHHV-6 (AIM 3) and compare the sequence to HHV-6A (strain U1102) and HHV-6B 
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(strain Z29).  To begin, genomic DNA was isolated from Family-1/Sibling-2 PBMCs and 
454-Sequencing was completed in collaboration with the University of Florida 
Interdisciplinary Center for Biotechnology Research.  454-Sequencing analyzed 156,609 
bp of the iHHV-6 genome, which correlates to a genome coverage of 98.3%.  Sequence 
identity between the genome of iHHV-6 and HHV-6A (strain U1102) was 97.2%, while 
only 88.3% sequence identity was shared with HHV-6B (strain Z29). 
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AIM III.  To Determine if the Chromosome Integrated Human Herpesvirus 6A 
Genome can Reactivate from Latency and Produce Infectious Virus 
 
TSA and TPA/Hydrocortisone can Induce Lytic Replication of Chromosome 
Integrated HHV-6A 
Experiments from AIM 1 and 2 provided substantial evidence that HHV-6A and 
HHV-6B achieves latency via integration into the telomeres of human PBMCs in vivo and 
following infection of T-cell lines and HEK-293 cells in vitro.  It appears that in cell lines 
capable of supporting productive, lytic infection, some of the cells also become latently 
infected through chromosomal integration, and remain viable.  Moreover, in neither the 
in vivo or in vitro studies did we find HHV-6 DNA in episomal form—the strategy by 
which other human herpesviruses achieve latency (Figs. 16, 17, and 24).  Therefore, it 
remained unknown whether iHHV-6 can reactivate from its integrated state to produce 
infectious virions, making integration a molecular strategy for viral latency. 
To determine if chromosomally-integrated HHV-6A and HHV-6B can reactivate, 
we collected HHV-6A integrated HEK-293 cells and T-cells from five patients with iHHV-
6 (Table 2 and 12).  These cells were cultured either in the presence trichostatin A 
(TSA)—a histone deacetylase inhibitor known to reactivate latent herpesviruses—or with 
12-O-Tetradecanoyl-13 acetate (TPA) and hydrocortisone for three days (106-110).  
Genomic DNA was then isolated from these cells and the increase in viral copies was 
determined by amplification of HHV-6 ORF U94 through quantitative real time PCR 
(qPCR).  TSA induced a 3.7 fold increase in viral copies for HEK-293 cells with 
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integrated HHV-6A and 1.4 fold increase in viral copies from patient T-cells with iHHV-6 
as compared to untreated control (Fig. 26).  TPA and hydrocortisone produced similar 
though milder effects.  
To determine if the increase in viral DNA copies resulted in the production of 
infectious virus, we cultured PBMCs from six members of Family-1 and Family-2 with 
TPA and hydrocortisone.  We then co-cultured these cells with Molt3 T-cell line in the 
presence of TPA and hydrocortisone.  After 2 weeks, lytic reactivation of iHHV-6 was 
evident by observing syncytia in the infected Molt3 cells (Fig. 27). 
 
 
 
Fig. 26.  HHV-6 DNA qPCR analysis of patient T-cells and in vitro latently infected 
HEK-293 cell lines induced by TPA and TSA.  T-cell cultures from five family 
members and three latently infected HEK-293/HHV-6A cell lines were cultured in AIM-V 
or DMEM medium supplemented with 10% FCS and treated with 20 ng/ml TPA, 1x10-6 
M hydrocortisone, and 80 ng/ml TSA for three days.  DNA isolated from cells (in 
triplicate) were subjected to quantitative real time PCR (qPCR) for ORF U94 and fold 
change ratios of Ct values normalized to beta actin were relative to untreated control.  
(a) HEK-293 (n=3) and (b) T-cells (n=5).  TSA promoted significant increase in viral DNA 
replication, while the stimulation with TPA and hydrocortisone had a milder effect.  
Statistical analysis was based upon the student T-test and p < 0.05 was considered 
significant. 
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Fig. 27.  Reactivation of iHHV-6A induces syncytium formation in a naïve T-cell 
line.  (a-d) Freshly isolated PBMC from Family-1/Sibling-2 stimulated with 20 ng/ml TPA 
and 1x10-6 M hydrocortisone.  PBMC were co-cultured with Molt3 cells for 2 weeks.  
Syncytium formation (400X magnification) was documented.  (e) Molt3 cells treated with 
TPA and hydrocortisone and (f) Molt3 cells untreated. 
 
To determine the stage of viral replication of iHHV-6A, we analyzed the 
reactivated virus isolated from Family-1/Sibling-2 PBMCs through the Gardella gel (88).  
Southern hybridization with HHV-6A cosmid probes demonstrated the lytic replication as 
shown by the presence of replicating iHHV-6A linear DNA and RNA (Fig. 28).  
Furthermore, sequencing of the DR region from latent chromosome-integrated iHHV-6A 
(Family-1/Sibling-2) PBMCs was identical to the reactivated virus cultured in the Molt3 
cells (Fig. A1).  This confirms the successful reactivation of integrated iHHV-6 from 
patient cells. 
Taken together, the data suggest that HHV-6A and HHV-6B are unique among 
human herpesviruses: they specifically and efficiently integrate into telomeres of 
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chromosomes during latency rather than forming episomes—the strategy by which other 
human herpesviruses achieve latency.  Moreover, the integrated viral genome is capable 
of reactivation to produce infectious virions.  Thus, the integration of iHHV-6A and iHHV-
6B is not an unusual dead-end phenomenon, but a means of achieving latency. 
 
 
 
Fig. 28.  Analysis of in vitro reactivated iHHV-6A patient PBMCs with the vertical 
agarose gel technique of Gardella et al. (88).  Gardella gel analysis of infected Molt3 
cells two weeks after co-culturing with PBMCs treated with TPA and hydrocortisone from 
Family-1/Sibling-2.  Hector 2 T-cell line carrying one copy of HHV-6A per a cell.  
Reactivation was shown through linear DNA and RNA detected with HHV-6A cosmid 
probe (84). 
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During Reactivation, the Integrated iHHV-6 Genome Replicates via Formation of 
Concatemers 
Reactivation of the integrated iHHV-6A virus from individuals’ PBMCs as well as 
cell lines was inducible after stimulation with TPA and TSA.  Co-cultivation studies 
indicated that the latent, integrated genome was capable of producing fully competent 
virus.  Reactivation of the integrated iHHV-6 resulted in the increase in viral copies 
(Figs. 26 and 28) and induction of syncytium (Fig. 27).  However, we set out to 
determine whether reactivation of iHHV-6 genome resulted in rolling-circle replication 
and the formation of concatemers and/or episomes of viral genomes similar to the 
replication of other herpesviruses (1, 26, 27). 
To reactivate HHV-6A (strain U1102) from latent integration, HEK-293 cells 
(Table 2) were cultured with TSA at concentration of 160 ng/ml, 80 ng/ml, 40 ng/ml, 20 
ng/ml, and 10 ng/ml for 3 days.  Detection of viral episomes and/or concatemers was 
completed by PCR amplification of the DR by two primers that annealed to either end of 
the U region of HHV-6A (Fig. 29a).  Thus amplification of DR would only occur during 
circularization of the viral genome or concatemers of HHV-6A genomes linked in a head-
to-tail conformation (26, 27, 47, 102, 111, 112).  Following co-hybridization with 
telomere, DR, and U HHV-6A oligonucleotide probes, hybridization of DR specific 
fragments was found in HHV-6A integrated HEK-293 cells treated with TSA (Fig. 29b).  
Furthermore, DR specific signal was also detected in control HHV-6A lytic infected Jjahn 
cells.  We also identified variability in the molecular weight of the amplified DR 
fragments.  The amplification of multiple molecular weight bands is possibly due to 
insertion of variable number of telomere repeats between DR and U during reactivation 
mediated by homologous recombination.   No hybridization was identified in either 
control HEK-293 and untreated HEK-293/HHV-6A, which illustrates the in vitro 
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reactivation of integrated HHV-6A is dependent on the histone deacetylase inhibitor 
TSA.  
In summary of AIM 3, reactivation of iHHV-6 genome after treatment with TSA 
resulted in rolling-circle replication and the formation of viral concatemers add/or 
episomes, which is similar to the replication strategy of herpesviruses (1, 26, 27). 
 
 
 
Fig. 29.  Reactivation of chromosome integrated HHV-6A from HEK-293 cells 
induces episome and/or concatemer replication.  (a) Schematic illustrating rolling-
circle replication of herpesviruses results in concatemers of viral genomes (1, 26, 27).  
Arrows indicate the location of primers utilized in the amplification of DR during lytic 
infection.  (b) HEK-293 cells with chromosome integrated HHV-6A (293/HHV-6A) and 
HEK-293 cells (negative control) were culture with TSA at concentration of 160 ng/ml, 80 
ng/ml, 40 ng/ml, 20 ng/ml, and 10 ng/ml for 3 days.  DR amplification and Southern 
hybridization with telomere, U, and DR oligonucleotide probes demonstrate rolling-circle 
replication following TSA treatment.  HHV-6A lytic infection of Jjhan cells (Positive 
control).  No amplification was detected in untreated 293/HHV-6A or 293 cells (Negative 
controls). 
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DISCUSSION 
 
HHV-6A/HHV-6B Achieves Latency through Chromosomal/Telomere Integration 
Overall, this study provides substantial evidence that HHV-6A and HHV-6B 
establishes latency through an alternative mechanism differing from other human 
herpesviruses (Fig. 30).  HHV6-A and HHV-6B integrates into the telomeres of human 
peripheral mononuclear cells in vivo (Figs. 15, 16, 17, 18, and 19), and following 
infection in Jjhan T-cells, Molt3 T-cells, and HEK-293 cells in vitro (Figs. 10, 11, 12, 13, 
and 14).  It appears that in cell lines capable of supporting productive, lytic infection, 
some of the cells quickly become latently infected through chromosomal integration, and 
remain viable.  Thus, HHV-6A and HHV-6B integration is not an unusual dead-end 
phenomenon, but an alternative means of achieving latency.   
Previous studies have used FISH to suggest that HHV-6 is capable of 
chromosomal integration (28-32, 98).  However, FISH cannot distinguish non-covalent 
linkage from integration.  In this dissertation, evidence that HHV-6A and HHV-6B can 
integrate comes from multiple complementary methods besides FISH (Figs. 10 and 15): 
chromosome-specific PCR (Figs. 13 and 19), sequencing (Figs. 14, 19, and A1) IPCR 
(Figs. 11 and 18), Gardella gels (Figs. 16, 17, and 28), Cs/Cl Etbr ultracentrifugation 
(Fig. 24), and two novel models (Figs. 10 and 12).  
The results illustrate that iHHV-6A and iHHV-6B integrate into the host genome 
via homologous recombination with human telomeres.  In particular, telomere integration 
of iHHV-6A and iHHV-6B occurs through recombination of the perfect telomere repeats 
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encoded in the DRR juxtaposed to the end of the chromosome (Fig. 30c).  Moreover, the 
tandem array of telomere repeats [(TTAGGG)n] at the end of chromosomes was shown 
to extend beyond the DRL of iHHV-6.  Therefore, the structure of the iHHV-6 is as 
follows: chromosome-subtelomere-(TTAGGG)5-41-DRR-U-DRL-(TTAGGG)n. 
 
 
Fig. 30.  Schematic comparing the genome structure of HHV-6 to germ-line 
inherited HHV-6 (iHHV-6).  (a) The linear HHV-6 genome contains a unique (U) region 
of ~143 kbp with left and right direct repeats (DR) of ~8 kbp at the termini.  Perfect and 
imperfect telomere sequence (TTAGGG) positioned at end of DR play role HHV-6 
chromosome integration into the telomere.  (b) Fluorescence in situ hybridization (FISH) 
of PBMCs from a patient with iHHV-6A integrated into the telomere of chromosome 22q.  
Metaphase chromosomes counterstained with DAPI (blue), cy5-PNA telomere probe 
(red), and FITC-conjugated HHV-6 cosmid probe (green).  (c) Genome structure of 
iHHV-6 in which HHV-6 DRR is fused with the telomere repeats near the chromosome 
subtelomere and the DRL fused with the remaining telomere repeat array (TTAGGG)n 
(33). 
 
We also found that the latent integrated genome of iHHV-6A was inducible after 
stimulation with TPA and TSA, and co-cultivation studies indicated that the latent, 
integrated genome was capable of producing fully competent virus (Figs. 26, 27, and 
28).  During reactivation, iHHV-6 is excised from the integrated genome via homologous 
recombination between flanking telomere sequences and generation of the DRR-DRL  
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junction signifies circularization and concatemer formation through rolling-circle 
replication (Fig. 29).  Moreover, in neither the in vivo or in vitro studies did we find HHV-
6 DNA in episomal form—the strategy by which other Human Herpesviruses achieve 
latency.  Taken together, the data suggest that HHV-6A and HHV-6B are unique among 
Human Herpesviruses: they have the potential to specifically and efficiently integrate into 
telomeres of chromosomes during latency in the absence of circular episomes. 
 
Reactivation of Chromosome Integrated HHV-6A/HHV-6B 
The current understanding of HHV-6A and HHV-6B chromosome integration and 
direct clinical link to disease is in its initial stages of development.  Nevertheless, over 
the last 20 years significant progress has been made.  Considering the clinical 
implications that iHHV-6 has when manifested into a patients’ DNA, it’s crucial to 
determine whether reactivation of virus occurs from its latent integrated state.  The first 
experiment conducted by Daibata et al. induced lytic genes and capsid mRNA 
expression from chromosomally integrated HHV-6 Burkitt’s lymphoma cell line through 
culturing with the phorbol ester TPA (28). 
Furthermore, results from AIM III demonstrate reactivation of iHHV-6A from 
patient T-cells as well as viral integration amongst HEK-293 cells and T-cell lines in vitro 
(33).  Reactivation was achieved by means of co-culturing patient T-cells with the HDAC 
inhibitor TSA or with TPA plus hydrocortisone.  Reactivation of the integrated virus 
induced increase in viral copies, while cytopathic effect was visibly evident by cell lysis 
and syncytium formation in a naïve T-cell line (Figs. 26, 27, and 28).  Moreover, partial 
and 454 sequencing of the viral genome confirmed the iHHV-6A reactivation from its 
latent integrated state (Fig. A1).  This evidence further demonstrates that chromosome 
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integration of iHHV-6 into telomeres is an alternative mechanism for a Human 
Herpesvirus to establish latency, reactivates, and possibly induces disease. 
 
Proposed Model for Latent HHV-6A/HHV-6B Chromosome Integration and 
Reactivation 
As previously discussed, integration of HHV-6A and HHV-6B into the telomeres 
of chromosomes is unique and alterative means for a human herpesvirus to establish 
latency (33).  Comparable, the chicken hepresvirus MDV also integrates into the 
telomeres of chromosomes during latency (39-41).  However, the mechanism of MDV 
integration differs from that of HHV-6A/HHV-6B as the genome of MDV integrates as 
long concatemers.  Furthermore iHHV-6A, iHHV-6B, and MDV can reactivate from their 
latent integrated state to produce a lytic infection of naïve T-cells through chemicals 
inducers (28, 33, 41).  However, the mechanism of iHHV-6A, iHHV-6B, and MDV 
telomere integration as well as reactivation remains to be fully elucidated. 
In this next section, we propose a model (Fig. 31) to explain how the integration 
of HHV-6A/HHV-6B into chromosome telomeres occurs during latency.  The process of 
integration emerges through homologous recombination between the viral and host 
telomere repeats.  During this process, we propose the binding of TRF1 and/or TRF2 
proteins to the viral encoded TTAGGG repeats [similar to the binding of EBV Orip 
TTAGGGTTA repeat (113, 114)].  This enables the linear HHV-6A/HHV-6B genome to 
sit proximally to the chromosome telomere and permit homologous recombination.  
Second, during the process of latency, ORF U94 may play a role in transcriptional 
repression of lytic viral genes expression and aid in the specific integration of HHV-6 into 
to the telomeres.  Similar actions were observed in the rep68/78 mediated integration of 
AAV-2 into chromosome 19q13.4 (115-117).  Third, reactivation of iHHV-6 from its linear 
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integrated state serves as a template for the replication of a linear dsDNA genome.  The 
induction of iHHV-6A, iHHV-6B, and MDV with HDAC inhibitors supports the notion that 
reactivation precedes chromatin decondensation (Fig. 32) (28, 33, 41).  This is followed 
by circularization via recombination of the telomere sequences flanking the viral genome 
and subsequent rolling-circle replication leads to concatemer formation of viral genomes 
linked in a head-to-tail tandem conformation.  Finally, cleavage of concatemers to unit-
length viral genomes takes place during encapsidation of the viral DNA.  Therefore 
future studies need to determine if telomere proteins (TRF1 and TRF2) and TERRA 
interact with the HHV-6A/HHV-6B encoded TTAGGG repeat and thus promote viral 
integration into the telomeres. 
 
 
Fig. 31.  Proposed model for HHV-6A/HHV-6B integration into chromosome 
telomeres.  (A) We hypothesizes that localization of the linear HHV-6A/HHV-6B 
genome to chromosome telomeres occurs through TRF2 and TRF1 bidding of 
chromosome and HHV-6 DR encoded telomere repeat.  (B) The viral rep gene ORF U94 
then promotes homologous recombination between viral and chromosome telomere 
repeats, (C) which results in the integration of HHV-6A/HHV-6B into chromosome 
telomeres.  The telomere integration event may also utilize alternative lengthening of 
telomeres (ALT) for recombination. 
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Fig. 32.  Proposed model for iHHV-6 in vitro reactivation.  (a) During latency, HHV-
6A and HHV-6B can integrate into the telomeres during in vivo and in vitro infection.  
However, reactivation of iHHV-6 can be achieved through culturing of latently integrated 
cells with TSA, or TPA plus hydrocortisone.  (b) Reactivation of the integrated iHHV-6 
results in genome replication through rolling-circle replication.  
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It has been estimated that 85% of all malignant and transformed cells have 
telomerase active in order to prevent telomere attrition (74).  However, in those 
remaining cells it is expected that telomere length is maintained through alternative 
lengthening of telomeres (ALT) (75).  The mechanism of ALT has yet to be fully 
characterized; however one method suggests that circular extrachromosomal telomeric 
repeats (T-circle) formed from the lost of the telomere-loop (T-loop) at the end of 
telomeres may serve as a template for telomere lengthening through rolling-circle 
replication (77-80).  Similarly, herpesviruses replicate their genome through rolling-circle 
replication to form a concatemer of linear viral genomes in a head-to-tail conformation 
(1, 26, 27).  Therefore, the telomere repeats found at the end of DRL and DRR of the 
HHV-6A/HHV-6B genome may serve as an initial template for telomere elongation 
through rolling-circle replication and thus allow the integration of the viral genome into 
telomeres similar to the ALT pathway. 
 
The Role of Human Herpesviruses Latency Genes in the Maintenance of the Latent 
Viral Genome 
KSHV:  LANA and EBV:  EBNA1 
Latency genes expressed by Human Herpesviruses promote maintenance and 
replication of the viral episome while inhibiting the expression of lytic genes (16).  
Examples of Herpesviruses latency genes include EBV nuclear antigen-1 (EBNA-1) and 
KSHV latency associated nuclear antigen (LANA) (35, 36).  The Epstein-Barr virus 
latency gene EBNA-1 was shown to bind to the origin of plasmid replication (OriP) of the 
EBV encoded TTAGGGTTA repeat (imperfect telomere repeat) in cooperation with 
telomere binding protein TRF2 binding (113, 114).  TRF2 and EBNA-1 binding of OriP 
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stabilizes the EBV episome during latency and enables the attachment of the EBV 
genome to metaphase chromosomes through protein-protein interaction (36, 114).   
Similarly, LANA binds within the KSHV terminal repeats (TR) to stabilize the viral 
episome (118).  Within the TR of KSHV, the transmembrane glycoprotein K1 promoter is 
responsible for activating the signaling pathways for lytic infection (119).  Therefore, the 
binding of LANA to the TR suppresses both transcription of K1 and lytic replication.  A 
second target for LANA to establish latency is through inhibition of Rta, which is an IE 
gene responsible for promoting lytic gene replication (120).  Lan et al. established that 
LANA has the ability to directly repress Rta’s promoter activity, and inhibit the auto-
activation of viral transcription.  Furthermore, the association of KSHV episome to 
chromosomes is achieved by binding LANA’s C-terminus to the TR of KSHV and the N–
terminus to histones H2A-H2B (35, 121). 
 
HHV-6:  ORF U94 
Currently, there are several lines of evidence suggesting that the unique gene 
ORF U94 encoded by HHV-6A and HHV-6B may have a role in the establishment and 
maintenance of latency.  First, the expression of ORF U94 transcripts were observed in 
latently infected PBMCs from healthy donors, while lytic viral transcripts were not 
expressed (122).  Second, lymphoid cell lines stably expressing ORF U94, were 
permissive to HHV-6A infection, however no cytopathic effect was observed.  There was 
a steady decline in copies of viral DNA and transcripts detected 22 days post-infection.  
Furthermore, the expression of ORF U94 decreased viral replication of 
betaherpesviruses CMV and HHV-7 (123).  Moreover, the ssDNA binding activity of ORF 
U94 may have an impact on viral replication through transcriptional regulation (124).  
This hypothesis is supported by studies that have shown ORF U94 to suppress H-ras 
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mediated transformation in NIH3T3 cells and inhibit HIV-1 LTR expression at the level of 
the promoter (125).  The transcriptional regulation by ORF U94 was further verified by in 
vivo and in vitro immunoprecipitation assay that indentified ORF U94 binding to the 
human TATA-Binding Protein (hTBP) (126).  hTBP functions as a subunit of the TATA 
box binding transcription factor TFIID.  This binding activity is a critical step for the 
formation of the pre-initiation complex.  Therefore, the transcriptional regulation of HHV-
6A/HHV-6B lytic genes could possibly occur through the interaction of ORF U94 with 
hTBP and thus create a mechanism by which HHV-6A/HHV-6B can shift from a lytic to a 
latent infection. 
Interestingly, ORF U94 shares 24% sequence identity with latency gene 
rep68/78, derived from the human adeno-associated virus type 2 (AAV-2) (127).  
Rep68/78 regulates viral gene expression and directs the site specific integration of 
AAV-2 into the AAVS1 site in chromosome 19q13.4 (115-117, 128).  The function of 
rep68/78 is through DNA binding, endonuclease, and helicase activities.  Furthermore, in 
a rep68/78 deficient AAV-2 model, the virus no longer integrates into the chromosome 
(129).  However, the expression of ORF U94 was able to complement the activity of 
rep68/78 and rescue the mutant AAV-2 virus to replicate and integrate.  Therefore, this 
suggests that ORF U94 may function as a latency gene and possibly facilitate HHV-
6A/HHV-6B specific integration into telomeres similar to its AAV-2 encoded rep68/78 
counterpart. 
Despite the fact that the 490 amino acids of ORF U94 shares only 24% 
sequence identity with rep68/78 (127), there are structural features that may exhibit 
similar biological functions (Fig. 33).  The ORF U94 C-terminus (residues 229-490 aa) 
corresponds to the helicase and ATPase domain of rep68/78.  Specifically, the 
sequence codes for Walker A and B motifs that form the core of the class SF3 helicase  
92 
 
 
 
 
 
Fig. 33.  Structural SWISS-MODEL and consensus sequence of HHV-6A ORF U94 
N and C-terminus.  (a) The predicted ribbon diagrams of the U94 N-terminus (15-206 
aa) corresponds to the AAV rep nuclease domain [Protein Data Bank (PDB) accession 
number 1uut (128)).  (b) The C-terminus (229-490 aa) of ORF U94 corresponds to the 
AAV rep helicase domain [PDB accession number 1s9h (130)] circled in blue.  (c) 
Consensus protein sequence of AAV-2 Rep78 illustrates the DNA-binding domain (DBD) 
and endonuclease (Endo) domain for the N-terminus of HHV-6A ORF U94.  (d) The 
consensus protein sequence of AAV-2 Rep40 helicase domain and C-terminus of HHV-
6A U94.  The Walker (A, B, B’, and C) motifs form the core of the SF3 helicase and the 
arginine (Arg) finger catalyzes ATP hydrolysis when the protein forms a hexamer 
structure. 
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active site and an arginine finger which is critical player in ATP hydrolysis (130).  
Furthermore, the N-terminus (15-206 aa) of ORF U94 corresponds to the DNA binding 
and endonuclease domain of rep68/78 (128).  It has been found that the N-terminus of 
ORF U94 has ssDNA-binding activity (124) and the endonuclease domain of rep68/78 is 
required for the site specific cleavage of the AAVS1 site which is shared by both the 
inverted terminal repeats of AAV-2 and chromosome 19q13.4 (128).  In conclusion, the 
structural features shared between ORF U94 and rep68/78 emphasizes the importance 
of elucidating the function of this protein and implications it may have on viral replication, 
integration, and latency. 
 
Possible Impact of HHV-6A/HHV-6B Integration on Telomere and Chromosome 
Stability 
Theoretically, the ability of HHV-6A and HHV-6B to integrate into the genome 
could alter the stability of individual chromosomes and the expression of adjacent 
subtelomeric genes.  Interestingly, subtelomeric rearrangement and deletions of 
chromosomes has been associated with mental retardation (131).  In a review of 1,718 
patients with mental retardation from 14 studies, 97 patients (5.8%) had subtelomeric 
rearrangements or deletions (132).  In particular, terminal deletion or subtelomere 
rearrangements of chromosome 17p13.3 PAFAH1B1 gene results in Miller-Dieker 
syndrome which is characterized by mental retardation, lissencephaly, growth 
deficiency, seizures, and facial abnormalities (133, 134).  de Grouchy syndrome is 
characterized by mental retardation, growth deficiencies, and hearing loss due to 
deletion of chromosome region 18q23 (133).  Moreover, genetic mapping of patients 
with bipolar disorders has identified a deletion at chromosome 18q23, however the link 
remains controversial and the specific locus has not been identified (135, 136).  In 
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conclusion, iHHV-6A and iHHV-6B integration into chromosomes 17p13.3, 18q23, and 
22q13.3 (Table 12) warrants direct sequencing and further cytogenetic analysis for 
chromosome deletions and rearrangements during integration. 
Potentially, the integration of iHHV-6A and iHHV-6B into the telomere of 
chromosomes could alter the expression of adjacent subtelomeric genes through the 
inhibition of telomere position effect (TPE) (137).  TPE is characterized by transcriptional 
repression of telomere adjacent genes through the recruitment of HDAC and histone 
H3K9 methylation emanating from the constitutive heterochromatin state of the telomere.  
The epigenetic regulation of TPE is well characterized in Saccharomyces cerevisiae 
(137-140).  The use of reporter systems (GFP, luciferase, URA3) has identified TPE in 
excess of 20 kbp downstream of the telomere sequence in S. cerevisiae.  However less 
established in human cells, Baur et al. observed a 10 fold decrease in the expression of 
telomere adjacent luciferase reporter when compared to reporter that was integrated 
near the centromere (141).  Moreover, the heterochromatin state of TPE was reversible 
after treatment of human cells with TSA.  This resulted in the suppression of HDACs and 
transcriptional activation of the luciferase reporter, which is similar to the TSA mediated 
reactivation of iHHV-6A and iHHV-6B from its latent integrated state (Figs. 26, 27, 28, 
29, and 32).  Therefore, further experiments are needed to determine if TPE plays a role 
in suppressing iHHV-6A and iHHV-6B lytic genes during latency, and whether the 
integrated viral genome alters the expression of nearby genes due to interruption of 
TPE. 
These findings might also have relevance for telomerase activity.  Mammalian 
and yeast chromosomes express a telomeric repeat-containing noncoding RNA 
(TERRA) (142).  TERRA is proposed to regulate telomerase and many important 
telomere functions (142), and TERRA transcription is initiated in the subtelomere (Fig. 
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34a).  Therefore, it’s possible that telomere integration of HHV-6A/HHV-6B could alter 
the expression of TERRA leading to dysfunction of telomerase or telomere chromatin 
decondensation (Fig. 34bc). 
The integration of HHV-6A and HHV-6B into telomeres is a newly identified form 
of human herpesvirus latency and the knowledge attained from the virus telomere 
biology may play a critical role in understanding the process of virus replication and 
integration.  The length of telomeres in somatic cells is 5-15 kbp and after every cell 
division, 250-300 bp are lost from the end of telomeres due to the challenges 
encountered with the process of end replication (70).  Cells reach the Hayflick limit once 
their telomeres reach a critical length, and undergo replicative senescence or apoptosis.  
  
 
 
Fig. 34.  TERRA expression and the possible impact of HHV-6A/HHV-6B telomere 
integration.  (a) The expression of the TERRA transcript is initiated in the chromosome 
subtelomere.  Alternatively, it’s unclear if HHV-6 integration alters TERRA expression.  
(b)  It possible that TERRA expression could be initiated in the DRR or DRL of HHV-6 or 
(c) the transcript is produced across the genome of HHV-6. 
 
Alternatively, telomeres can be lengthened by telomerase reverse transcriptase 
(TERT) through the addition of the TTAGGG repeat (70).  Telomerase mediated 
telomere lengthening has been detected in germ-line cells, cancer cells, and stem cells. 
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The repetitive telomere sequence and the complex of six telomere associated proteins 
protect the ends of chromosomes from double stranded breaks, chromosome fusions, 
and inhibits telomerase mediated lengthening (68, 69).  The complex of telomere 
associate proteins known as the shelterin complex contains: TRF1 (TTAGGG Repeat 
Factor 1), TRF2 (TTAGGG Repeat Factor 2), and Pot1 (Protection of Telomeres 1) 
directly bind to the telomeric TTAGGG repeat.  The complex protein interaction of the 
shelterin complex is maintained through TIN2 (TRF1-Interacting Nuclear Factor 2), TPP1 
(TINT1, PIP1, PYOP1), and RAP1 (Repressor Activator Protein 1).  In turn, TERRA  
stabilizes the shelterin complex and facilitates telomere heterochromatin formation 
through the direct interaction with TRF1 and TRF2 (72). 
From the six shelterin proteins, TRF2 was shown to bind to the three nonamer 
EBV encoded TTAGGGTTA repeat (imperfect TTAGGG repeat) within the origin of 
plasmid replication (OriP) in cooperation with viral latency gene EBNA-1 (113, 114).  
TRF2 and EBNA-1 binding of OriP stabilizes the EBV episome during latency and 
enables the association of the viral genome to metaphase chromosomes (36, 114).  This 
mechanism ensures division of the EBV genome amongst daughter cells during mitosis.  
Moreover, Lieberman et al. also found that EBNA-1 directly interacted with TERRA, 
however the principle of this interaction has not been fully elucidated (72).  Similarly, we 
hypothesize that the binding of telomere repeats encoded in the DR of HHV-6A and 
HHV-6B by TRF2/TRF1 plays a role in telomere mediated integration by facilitating the 
localization of the viral genome to the telomere of chromosomes (Fig. 31).  This in turn 
promotes homologous recombination of the viral telomere repeats and that of the 
chromosome telomere. 
The integration of iHHV-6A and iHHV-6B into the same chromosome telomeres 
of family members lends itself to vertical transmission through the germ-line (Table 12) 
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(32, 33, 143).  Moreover, studies have shown that iHHV-6A and iHHV-6B preferentially 
integrates into telomeres of chromosomes 9q34.4, 17p13.3, 18q23, 19q13.4, and 
22q13.3 (28, 29, 32, 33, 144).  These results may be explained by three different 
mechanisms.  First, a number of chromosome ends may be more accessible for 
homologous recombination between the viral and chromosomal TTAGGG repeats due to 
heterochromatin structure of the chromosome telomere.  Alternatively, HHV-6A/HHV-6B 
may integrate randomly into all 92 telomere regions at the end of chromosomes, but the 
integrated genome may be unstable in some telomeres (33).  After a series of cell 
divisions, it’s possible that cells with unstable chromosomes would be “negatively” 
selected over those with stable chromosomes.  Finally, telomere integration could have 
occurred as a single event and thus inheritance of the genome occurs through multiple 
generations.  
Results thus far have shown that between in vivo integrated iHHV-6 amongst 
patients and in vitro integrated cell lines, the viral DRR of the genome is integrated within 
5 - 41 telomere repeats from the end of the chromosome (Figs. 14, 19, and 30) (33).  
The proximity of the ~160 kbp iHHV-6 genome integrated between the end of the 
chromosome and tandem array of telomere repeats suggests that the virus has a 
minimal impact on the telomere/shelterin complex.  However, if the iHHV-6 genome was 
to integrate near the end of the telomere, one would expect progressive shortening of 
the telomere leading to loss of sequences from the viral genome.  Subsequently, this 
loss may lead to chromosome instability as the result of chromosome fusion, replicative 
senescence, or the inability of the shelterin complex to bind the non-telomere coding 
sequence of the virus to form the cap at the end of telomere. 
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Transmission of iHHV-6A/iHHV-6B via the Germ-Line 
Following primary infection, HHV-6A/HHV-6B establishes a latent infection 
primarily within monocytes/macrophages and in the salivary gland (10, 16).  It is believed 
that the predominant means of acquiring HHV-6A/HHV-6B is the result of horizontal 
transmission through viral shedding from the saliva of infected individuals to uninfected 
infants and children.  However, vertical transmission of inherited HHV-6 (iHHV-6) 
through the germ-line has proven to be a novel mechanism by which the virus integrates 
during latency.  Daibata et al. described the first reported case of iHHV-6 vertical 
transmission through the germ-line of parent to their child (145).  This initial observation 
was confirmed by several other laboratories (32, 33, 98, 143).  In each of these reports, 
both parents and children with iHHV-6 contained identical sites of chromosome 
integration (Table 12 and Fig. 15).  Furthermore, the same virus strain of iHHV-6 was 
inherited through the germ-line between parent and child.  This was evident because 
iHHV-6 integrated in each family member contained similar restriction fragment 
polymorphism profiles and similar sequence of select viral genes (Fig. 25, Table 12, and 
Fig. A1) (33). 
Additional evidence supporting vertical transmission of the iHHV-6 genome was 
described in a study showing cases of HHV-6 congenital infection obtained through 
germ-line transmission or transplacental infection of the fetus (98).  It was reported that 
from a total of 254 infants enrolled in a study, 16.9% (43/254) had acquired a congenital 
HHV-6 infection and 16.5% (42/254) acquired HHV-6 through primary infection by 36 
months.  Furthermore, the majority of congenital HHV-6 was acquired through germ-line 
in which, 14.6% (37/254) infants were positive for iHHV-6 and only 2.4% (6/254) had 
acquired HHV-6 through transplacental infection.  Furthermore, germ-line transmission 
results in viral integration within the chromosome of every cell that resides in the 
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individual.  This statement coincides with the information previously describing the viral 
load of patients consistently detected at or above 1 copy per cell (32, 33, 98, 143). 
Frequently observed in hematopoietic stem cell transplant patients, HHV-6 may 
reactivate and induce graft rejection, bone marrow suppression, and encephalitis (1, 16, 
22).  Moreover, even after ablation of the recipient’s bone marrow in preparation for 
transplantation, it has been shown that the donor stem cells may transfer iHHV-6 to the 
recipient (144, 146, 147).  This results in the subsequent rise of HHV-6 viral copies 
within the recipient peripheral blood as well as introduction of iHHV-6 positive stem cells.  
Investigations are also necessary to understand how immunosuppressive agents used 
to prevent graft rejection affect iHHV-6 infected patients.  Will clinicians also have to 
consider screening for iHHHV-6 during blood donations?  The initial studies on the 
transmission of integrated iHHV-6 into chromosome of hematopoietic stem cells during 
transplantation has not been studied sufficiently, and additional studies must be 
performed to understand the long-term effects on those patients who received stem cell 
transplants with iHHV-6.  
 
Possible Pathologies Associated with Vertically Transmitted iHHV-6A/iHHV-6B 
The documentation of integrated iHHV-6 also raises important questions.  Is the 
immune system of patients born with iHHV-6 tolerant of any viral antigens?  Given that 
the viral genome is present in every cell and capable of producing competent virions, are 
these patients at particular risk for any diseases? Are the patients susceptible to 
superinfection with another strain of HHV-6A, or to infection with HHV-6B?  Answers to 
these questions await further study. 
HHV-6A and HHV-6B infection occurs by means of attachment and entry into 
cells through the complement regulator receptor CD46 (25).  The diverse cell tropism 
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and multiple disease associations with HHV-6A/HHV-6B are due, in part, to the 
expression of CD46 present on the surface of all nucleated cells.  In particular, HHV-6B 
primary infection of young children is the etiological agent of exanthema subitum 
(roseola), which is characterized by high fever, diarrhea, and a mild skin rash along the 
trunk, neck, and face (5, 12).  There is no classic textbook clinical disease caused by 
HHV-6A at this time.  However, HHV-6A has been suggested to act as a co-factor in 
AIDS progression by contributing to the killing of CD-4 lymphocytes (11, 20, 54) and 
enhancement of HIV replication through activation of the long terminal repeats (LTR) 
(21).  Following primary infection, reactivation of HHV-6A/HHV-6B in immune 
compromised patients has led to graft rejection in solid organ and bone marrow 
transplants, seizures, and encephalitis (6, 16-19, 53).   
Patients with iHHV-6 present a wide range of symptoms and various diseases 
associated with the integrated viral genome, while other patients show no signs of 
clinical disease (Table 12) (28-34, 64, 67, 98, 144).  It remains unknown why some 
patients’ manifest neurological symptoms of the disease and others don’t.  However in 
vitro iHHV-6 reactivation of patient T-cells (28, 33), suggests that the virus may be in a 
latent integrated state in patients showing no signs of disease, while patients presenting 
symptoms of disease may have iHHV-6 reactivated from its integrated state. 
Furthermore, when considering the transmission of iHHV-6 through the germ-
line, in every cell of the patient there is at least one integrated copy of the viral genome 
(32, 33, 98, 143).  Reactivation can occur in any number of tissues within the body of the 
patient, which can lead to cell death, changes in cell function attributed to viral gene 
expression, and subsequent spread to neighboring CD46+ cells.  Therefore, the ability of 
HHV-6A/HHV-6B to infect the majority of nucleated cells through CD46 and the 
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presences of iHHV-6 integrated in every cell sheds light on the various symptoms and 
diseases associated with this virus. 
However pertaining to iHHV-6, the direct clinical link between neurological 
disease and active viral replication is still underway.  It remains uncertain if CNS 
dysfunction is due to reactivation of iHHV-6 or if the virus is merely an opportunistic 
infection within the brain.  However, antiviral therapy has initially shown some short term 
success in reducing neurological symptoms associated with iHHV-6 (148). 
 
HHV-6A/HHV-6B and Malignant Diseases 
Previous studies have evaluated patients with HHV-6A/HHV-6B presenting 
neurological symptoms and various lymphomas, which include Hodgkin’s lymphoma, 
Burkitt’s lymphoma, acute lympoblastic leukaemia (ALL), chronic myelogenous leukemia 
(CML), and acute myeloid leukemia (AML) (28, 34, 110, 145, 149, 150).  However, the 
prevalence of HHV-6A/HHV-6B in children with ALL and AML does not differ significantly 
from the healthy populations (150).  Therefore the direct clinical link between cancer and 
HHV-6A/HHV-6B is not completely conclusive, but reactivation of the virus can be linked 
to graft rejection in hematopoietic stem cell transplant patients treated with 
immunosuppressive drugs (16, 53). 
HHV-6A/HHV-6B may not play a direct role in cancer development, but these 
viruses may play a role in cancer progression by complementing oncogenic viruses in an 
environment that condones cancer development.  Similarly, HHV-6A has the ability to 
increase HIV replication through activation of the long terminal repeats (LTR) and 
enhance AIDS progression in macaques (20, 21).  Also, HHV-6A/HHV-6B can increase 
RNA expression of human papillomavirus virus (HPV) oncogenes E6 and E7 in cervical 
epithelial cells (151).  HHV-6A/HHV-6B and HPV co-infection of cervical epithelial cells 
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increased production of E6 and E7 RNA and accelerated tumor growth in mice by 3 
weeks as compared to the 6 week time period normally expected with HPV infection 
alone. 
During the course of human evolution, human endogenous retroviruses (HERV) 
integrated into the germ-line roughly 10 million years ago (152).  HERVs no longer 
produce mature virus due to mutations and deletions in their sequence, however in a 
study by zur Hausen et al., HHV-6 induced transcription of gag, pol, and env genes from 
HERV found in normal PBMCs and in cell lines (153).  Moreover, HERV env protein has 
also been found to be expressed in various cancer cells.  Duelli et al. hypothesized that 
cell fusions caused by endogenous viruses and syncytium-forming viruses like HHV-6 
can lead to aneuploidy and subsequently induce chromosome instability and malignant 
transformation (154).  Therefore the ability of HHV-6 and HERV to induce cell fusion, 
and increase expression of HERV env protein by HHV-6, emphasizes the need of further 
clinical studies to determine the potential impact of HHV-6 and iHHV-6 on cancer as well 
as their effect on MS, CFS, DRESS, and bone marrow suppression in transplants.  
 
Prevalence of Chromosome Integrated iHHV-6 in the Healthy Population; Not Yet 
Identified Diseases? 
To appreciate the significance of latent iHHV-6 integration into the telomere of 
chromosomes, several studies have investigated the prevalence of iHHV-6 integration 
amongst congenital infection, normal blood donors, and hospitalized patients (64, 65).  
The prevalence of iHHV-6 chromosome integration with high viral loads (106-107 copies 
per ml of blood) has been described in several British cohort studies (Table 13) (64, 65).  
In normal healthy blood donors it was found that 0.8 % (4/500) (64) and 1.0 % (57/5638) 
(81) had high viral loads most likely attributed to iHHV-6 integration in the germ-line.  In 
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contrast, prevalence of integrated iHHV-6 in hospitalized patient was higher, 2.9 % 
(13/449) (64) and 3.3 % (6/184) (65).  In conclusion, the transmission of iHHV-6 through 
the germ-line and its prevalence in the population implies the necessity for research to 
characterize the significance and possible pathologies of iHHV-6 integration.  Moreover, 
it is essential that researchers determine the overall impact the integrated virus may 
have on hospitalized patients and understand disease progression associated with 
iHHV-6. 
 
Table 13.  Prevalence of chromosome integrated iHHV-6 among patients and 
blood donors. 
Authors Location Individuals Positive 
Griffiths (155) London, UK Liver transplant pt 3/60 (5 %) 
Kidd (156) London, UK Renal transplant pt 1/52 (1.9 %) 
Ward (65) London, UK Encephalitis 6/184 (3.3 %) 
Tanaka-Taya (32) Japan Hospitalized pt 5/2332 (0.21 %) 
Leong (64) London, UK Hospitalized pt 13/449 (2.9 %) 
Ward (65) London, UK Blood donors 10/653 (1.5 %) 
Leong (64) London, UK Blood donors 4/500 (0.8 %) 
Hall (81) Rochester, NY Cord blood donors 57/5638 (1.0 %) 
 
Summary and Future Directions 
We hypothesized and established by a broad range of experiments that during 
latency, the Human Herpesvirus 6A and 6B genome integrates into the telomeres of 
human chromosomes through homologous recombination with the n(TTAGGG) viral 
repeats, while transmission can occurs through the germ-line.  Furthermore, we have 
demonstrated the induction of the integrated virus to lytic replication.  The second 
objective of this dissertation was also achieved as the data contributes to our 
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understanding of HHV-6A/HHV-6B latency and pathology as well as presents the current 
and preceding knowledge of iHHV-6.   
Since HHV-6A and HHV-6B are both important pathogens, our studies provide 
several tools for future clinical investigations.  Over 90% (or more likely 100%) of the 
population has acquired a primary HHV-6 infection by three years of age and the virus 
remains latent for the life of the host (13, 14).  Investigators have established that HHV-
6B is the etiological agent of roseolla and HHV-6A is identified as a cofactor in AIDS 
progression (6, 16-21, 53, 55-57).  HHV-6A is perhaps associated with MS, while both 
HHV-6A and HHV-6B are linked to graft rejection in transplants, and various neurological 
disorders.  Integration of HHV-6A and HHV-6B in telomeres may explain some of the 
clinical symptoms associated with these diseases.   
Future experiments need to determine the overall clinical impact of germ-line 
integrated iHHV-6A/B.  Furthermore, there is a need to determine the relationship 
between HHV-6A/HHV-6B infection and MS, CFS, cancer, AIDS progression, and 
various neurological disorders.  Second, determine the physiological effect and impact 
on the stability of iHHV-6 has on telomeres during integration.  This questions is of 
interest to investigators since telomere shortening leads to cell senescence and/or 
telomerase activation, which is a hallmark of chromosome instability (69).  Third, 
characterize the molecular switches that dictate whether, following new infection in a cell 
line capable of sustaining productive lytic infection, alternatively, the virus integrates and 
establishes latency.  Fourth, determine the switches that activate transcription of lytic 
genes leading to reactivation of iHHV-6.  Fifth, investigate whether the viral latency gene 
ORF U94 and telomere binding proteins TRF1 and TRF2 do in fact play a role during the 
process of telomere integration.  Sixth, evaluate the effect of TPE on virus reactivation 
and disruption of transcriptional repression of telomere adjacent chromosome genes.  
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Seventh, determine if the TTAGGG repeats encoded in DR of HHV-7 promotes viral 
telomere integration similar to HHV-6A/B and MDV. 
The use of BAC vectors to clone the entire genome of herpesviruses are 
instrumental in understanding the means by which viruses replicate, while the creation of 
knockout-mutants characterize viral proteins.  To begin to answer some of the questions 
listed above, initial attempts to generate an infectious HHV-6 BAC cloned virus were 
unsuccessful (46, 102).  However, Arbuckle et al. were the first to successfully produce 
an infectious HHV-6A virus that expresses GFP and a selectable marker (33).  This 
reproducible cloning system was then verified by Tang et al. (103).  The knowledge 
obtained from HHV-6A and HHV-6B integration and the adaptation of recombinant HHV-
6 viruses should facilitate understanding of the clinical impact viral latency/integration 
has on the host. 
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Fig. A1.  Multiple sequence alignment of ORF U94 and direct repeat from 
chromosomally integrated and reactivated iHHV-6A.  ORF U94 was amplified with 
primers U94L-1, U94L-2, U94R-1, and U94R-2; while the left repeat was amplified with 
primers LTR-1 and LTR-2 from genomic DNA isolated from chromosomally integrated 
family members. Alignments were completed with ClustalX 2.0 multiple sequence 
alignment software. 
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